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11 ABSTRACT
Loss of work capacity is a serious consequence of rheumatoid arthritis (RA), and until recently, 
the rate of permanent work disability has been high despite development of antirheumatic 
therapy. The Finnish Rheumatoid Arthritis Combination-Therapy Trial (FIN-RACo), begun in 
1993, provided an opportunity to investigate the impact of antirheumatic drug treatment on the 
maintenance of work capacity and to explore risk factors for decreased ability to work. The 
national social insurance registers offered objective data on sick leaves and longer-term work 
disability and enabled estimation of the monetary value of this outcome with high accuracy.  
In the FIN-RACo trial, 195 patients with recent-onset, active RA were randomized to receive 
either a combination of disease-modifying antirheumatic drugs (DMARDs) (sulfasalazine, 
methotrexate, hydroxychloroquine) and prednisolone, or a single DMARD with or without 
prednisolone for 2 years, after which, drug-treatment strategy became unrestricted. The 
patients were followed up with regular check-up visits for 5 years. The present study focuses 
on the 162 patients who were working or at least available for work at baseline. After a 5-year 
followup, data on sick leave and retirement came from social insurance registers or case 
records. The cumulative duration of sickness allowance periods and RA-related disability 
pensions was calculated for each patient. 
The cumulative number of work disability days per patient-observation year was significantly 
lower in the combination-therapy group than for patients who initially received a single-
DMARD therapy; sex- and age-adjusted medians (95% confidence interval, CI) were 18 days 
(5–31) and 37 days (24–50), respectively (P = 0.009). 
The monetary value of productivity loss due to RA-related days off work was estimated on the 
basis of sickness allowances paid, which, in turn, had been calculated according to individual 
incomes assessed by Finnish tax authorities. A total of 120 (75%) patients, women more often 
(82%) than men (61%), used sick leave or experienced longer-term work disability, or both, 
which led to loss of productivity. The value of annual productivity of those 120 patients 
averaged US$35,991 (95% CI 32,762–39,221). By the human capital approach, mean lost 
productivity per patient-year for the group of 162 patients was $8,805 (95% CI 6,784–11,160). 
The value of lost productivity was highest during the first year, resulting mainly from sick 
leave (89%); thereafter, permanent work disability dominated. 
Loss of productivity was inversely related to improvement in RA over the followup, and was 
associated with increase in number of erosions. Even a slight functional disability as measured 
by the Stanford Health Assessment Questionnaire (HAQ) at 6 months led to increased age- and 
sex-adjusted odds for higher productivity losses. When the HAQ was linked to the 
International Classification of Functioning, Disability, and Health (ICF), “changing and 
maintaining body position” was the only ICF subcategory independently associated with loss 
of productivity.
High scores (?50) in patient’s and in physician’s global assessment of RA severity (visual 
analogue scale, VAS 0 to 100) appeared as baseline risk factors for extension of work 
disability, in addition to low education level (<10 years of schooling), older age, and high 
HAQ score (? 1.0). Combination therapy was a protective factor. 
2Early treatment response had a strong impact on maintenance of patients’ work capacity. None 
of the 44 patients in remission at 6 or 12 months became permanently work disabled over the 
5-year followup, whereas 56% of the patients without 20% improvement at 6 months ended on 
a permanent RA-related disability pension.  
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54 INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune disease of unknown etiology 
characterized by chronic synovial joint inflammation causing pain, stiffness, and impaired 
function. Formation of rheumatoid pannus, an inflammatory and invasive tissue, eventually 
leads to joint destruction. Because of the lack of any specific feature or test, RA diagnosis is a 
composite of clinical and investigational features. For research purposes, the generally 
approved classification criteria used are the American College of Rheumatology (ACR; 
formerly, the American Rheumatism Association) 1987 revised criteria for RA (Arnett et al. 
1988). Rheumatoid arthritis occurs worldwide, affecting about 1% of the population (Silman 
2001), but is rare in less developed rural parts of the world and more common in industrialized 
countries (MacGregor and Silman 2003).  
The course of RA varies, but in clinic-based cohorts it is most often progressive with more or 
less continuous disease activity and tissue damage. This chronic nature of RA frequently 
results in functional disability of various degrees with considerable consequences for the 
patients as well as for society (Conaghan et al. 1999, Griffith and Carr 2001, March and 
Lapsley 2001). For patients of working age, diminished ability to perform their current jobs 
and cessation of working life are frequent and serious outcomes occurring early in the course 
of the disease (Shanahan and Smith 1999, Sokka 2003). For permanent work disability, older 
age, fewer years of schooling, a physically demanding job, and longer duration and severity of 
RA are among the most common risk factors (Reisine et al. 1995, Mau et al. 1996, Wolfe and 
Hawley 1998, Sokka and Pincus 2001,Young et al. 2003, Verstappen et al. 2004, de Croon et 
al. 2004). Wide agreement prevails that the most expensive consequence of RA is loss of 
productivity (Pugner et al. 2000, Cooper 2000, Ruof et al. 2003). Previous studies have, with 
few exceptions, evaluated only productivity lost because of permanent inability to work. Sick 
leaves have been included in analyses in only three studies. In two studies of early RA, 
monetary estimations were based on the average income of all gainfully employed persons in 
that particular country (Merkesdal et al. 2001, Hallert et al. 2004). The third study utilized 
individual income data to estimate productivity losses in a cohort with a mean RA duration of 
8.4 years (Ruof et al. 2003). 
6The bulk of evidence indicates that disease-modifying antirheumatic drugs (DMARDs) not 
only relieve symptoms of RA but also improve long-term outcome, including limitation in 
radiographic damage and maintenance of good physical function (Fries et al. 1996, van der 
Heijde et al. 1996, Munro et al. 1998, Abu-Shakra et al. 1998, Stenger et al. 1998, Pincus and 
Sokka 2001). Some studies show that treatment with a combination of DMARDs provides a 
better response than does single-DMARD therapy (O´Dell et al. 1996, Boers et al. 1997, 
Calgüneri et al. 1999, O’Dell et al. 2002).  In the Finnish Rheumatoid Arthritis Combination-
Therapy Trial (FIN-RACo), a randomized clinical trial conducted from 1993 to 2000, the 
patients with recent-onset RA treated for 2 years with a combination of three DMARDs and 
prednisolone achieved significantly more remissions at 2 years than did those who received a 
single DMARD with or without prednisolone (Möttönen et at. 1999). Further, the aggressive 
initial combination therapy was superior in limiting peripheral joint damage for at least 5 years 
(Korpela et al. 2004). Until lately, no clear evidence has emerged that treatment improvements 
have altered the rate of work disability (Allaire 2001), but recent study shows an association 
between higher employment rates and etanercept use (Yelin et al. 2003). 
The present study is a prospective cohort substudy of the FIN-RACo. A total of 162 patients 
with recent-onset RA, aged 18 to 65 and available for the workforce at study entry, were 
followed up for 5 years. Data on sick leaves and disability pensions came from the registers of 
the Social Insurance Institution and the Central Pension Security Institute. Individual incomes 
before contracting RA were calculated on the basis of the amount of sickness allowance. The 
cumulative number of RA-related work disability days per patient-year were calculated; loss of 
productivity by the human capital approach (Koopmanschap and Rutten 1996) was estimated 
for each patient. Baseline predictors and impact of drug treatment response on the outcomes 
underwent analysis.
75 REVIEW OF THE LITERATURE
5.1 What is called rheumatoid arthritis (RA)?
Because rheumatoid arthritis has variable clinical features, lacks any pathognomonic sign, 
symptom, or laboratory test, and is of unknown etiology, we must define by convention what 
we mean by “rheumatoid arthritis.” Generally applied classification criteria are needed for the 
proper conduct of studies as well as for comparison and interpretation of results. The currently 
accepted classification scheme for rheumatoid arthritis is based on the 1987 American College 
of Rheumatology (ACR, formerly the American Rheumatism Association, ARA) criteria 
(Arnett et al. 1988, Table 1). These criteria fail, however, to rule out the possible 
heterogeneous etiology of clinical RA. 
Table 1. American College of Rheumatology (ACR) 1987 classification criteria for RA.  
For classification purposes, a patient has RA if at least four of the seven criteria are satisfied. 
Criterion must have been present 
for at least 6 weeks
1  Morning stiffness of ? 1 hour + 
2  Arthritis in 3 or more joint areas1 + 
3  Arthritis in a hand joint (PIP, MCP, wrist) + 
4  Symmetric swelling of 1 joint area (as defined in 2) + 
5  Rheumatoid nodules 
6  Positive rheumatoid factor (RF) 
7 Radiographic changes in hand and/or wrist joint2
1 Right or left proximal interphalangeal (PIP), metacarpophalangeal (MCP), wrist, elbow,  
   knee, ankle, and metatarsophalangeal (MTP) joints. 
2 Erosions or periarticular osteopenia present.
85.2 Epidemiology of RA 
RA prevalence has been between 0.5% and 1.0% in studies across Europe, North America, 
Asia and South Africa (Silman 2001). In the Finnish Mini-Finland study carried out during 
1978-80, the prevalence of seropositive RA in the population ?30 years of age was 0.8% (Aho 
et al. 1989 and 1998). Most studies have found a female-to-male excess of 2- to 4-fold. In all 
studies, age-specific prevalence rates increased with age.
The annual RA incidence in Finland was 39/100,000 in 1980 and 1985, and 32/100,000 adults 
in 1990 and 1995 (Kaipiainen-Seppänen and Aho 2000, Kaipiainen-Seppänen 2004). Between 
1975 and 1995 in Finland, the peak of incidence rose by 9 years and peaked in 1995 in the age-
group 65 to 74 (Kaipiainen-Seppänen et al. 1996). Despite this possibly declining incidence, 
the growing number of older people means an increasing number of individuals with RA. 
Incidence in females is greater than in males, with the exception of the oldest age groups. 
5.3 Etiology
The etiology of RA is unknown, but both genetic and environmental factors are of significance 
in its initiation and perpetuation (Carty et at. 2003, Klareskog et al. 2004). Its familial nature 
has long been known. Siblings of persons affected with RA have a 2- to 4-fold risk for 
developing the disease when compared with unrelated individuals. Smoking has been a risk 
factor for RA both in cross-sectional and longitudinal studies (Aho and Heliövaara 2004), and 
it also worsens disease outcome. 
5.4 Pathogenesis of RA 
Immunological events are typical for RA pathogenesis (Ollier et al. 2001). The vast majority of 
scientists are of the opinion that the initiation of RA is a T cell-mediated, antigen-specific 
process (Firestein 2003). The arthritogenic agent may be a retrovirus, a bacterial product, or 
some other organism. In a susceptible host, an early T cell response results in production of T 
cell cytokines and, consequently, in recruitment of other inflammatory cells into affected 
tissues. The synovium becomes a locally invasive and destructive “pannus” which is 
9responsible for the marginal erosions at the synovial interface of cartilage and bone 
characteristic of RA. Immunoglobulins with rheumatoid factor (RF) activity are secreted in 70 
to 90 % of patients (van Paassen et al. 2003). 
5.5 Clinical manifestations of RA 
RA is a systemic disease, but the most prominent feature is arthritis with typical symptoms of 
inflammation: tumor, calor, dolor, functio laesa (swelling, local heat, tenderness, and limited 
range of movement with stress pain) (Gordon and Hastings 2003, Woolf 2003). Erythema 
(rubor) of a joint is not, however, characteristic. The most common presentation is symmetric 
arthritis of the small peripheral joints. Other synovial structures—tendon sheaths and bursae, 
are also frequently affected. Onset may be acute, subacute, episodic (palindromic), or 
insidious, the latter being the most common type. Morning stiffness of joints lasting for at least 
an hour is one of the ACR 1987 classification criteria. Constitutional symptoms of 
inflammation such as fatigue, weight loss, and even fever are common and may occur early in 
the course.
The clinical course of RA is variable. It may sometimes be self-limiting or episodic but mostly 
is prolonged and progressive, resulting in increasing joint damage and destruction recognized 
clinically or radiologically (Ollier et al 2001). Clinical observations include reduced range of 
movement, collateral instability, malalignment, and subluxation with characteristic deformities 
especially in the hands and the feet. The key radiographic findings include fusiform soft tissue 
swelling, regional or periarticular osteoporosis, marginal or central osseous erosions and cysts, 
and diffuse loss of joint space. The development of joint destruction starts early and is most 
rapid during the first months of RA (Larsen and Thoen 1987, van der Heijde et al. 1992). The 
foot joints are usually affected earlier and in larger numbers than are the hand joints. Several 
scoring systems exist for radiographic evaluation of RA abnormalities.  
Some studies report that the outcome of RA in women is worse than in men (Kuiper et al 
2001); on women, disability and disease activity scores tend to be higher (Hallert et al. 2003, 
Tengstrand et al. 2004), with no gender difference in radiographic joint damage. 
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Inflammation may extend beyond synovial structures, causing nodules, sicca complex, 
serositis, and vasculitis (Matteson 2003). Osteoporosis of both the appendicular and axial 
skeleton develops early (Green and Deodrah 2001), and diffuse interstitial pulmonary fibrosis 
may occur. An elevated risk for coronary heart disease is associated with RA, and patients 
show higher mortality rates than in the general population with cardiovascular disease the most 
common cause of death (Mutru et al. 1985, Myllykangas-Luosujärvi et al. 1995). 
5.6 Disability in RA 
Inflammation of joints and other synovial structures, joint damage, and constitutional 
symptoms of RA lead to such problems as restriction in joint motion and decline in muscle 
strength, in a word: impairment of body functions (Stucki and Kroeling 2000, Gordon and 
Hastings 2003). This results in diminished capacity to perform tasks and, furthermore, to 
participate in social relationships.
The traditional biomechanical concept of disability includes only impaired physical 
functioning measured by clinical judgment, by observing patient performance, or by patient-
reported assessment (van Gestel and Stucki 1999). Self-report questionnaires are the most 
popular instruments, although discrepancies may occur between patient-reported performance 
and actual performance. The Stanford Health Assessment Questionnaire (HAQ) (Fries et al. 
1980) is the most widely used questionnaire for RA patients (see section 5.7). In early RA, 
HAQ disability is mainly a result of inflammation and pain, whereas the significance of 
structural damage as a cause of disability tends to grow progressively over time (Scott et al. 
2000, Welsing et al. 2001). Only a minor correlation between HAQ disability and disease 
duration exists, however, and persistent variation in disease activity remains the major 
determinant of disability (Wolfe 2000, Kirwan 2001). Baseline factors associated with adverse 
prognosis for functional capacity have been explored in many studies (Ollier et al. 2001, 
Combe et al. 2003). In all studies reported, the HAQ disability itself has been a risk factor. 
Other predictors of future functional disability include older age, female gender, positive 
rheumatoid factor, and more joints affected (Harrison et al. 1996, Wiles et al. 2000, Hallert et 
al. 2003). 
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Physical disability impacts on social and personal aspects of life, resulting in handicap (Griffith 
and Carr 2001). People with RA differ from controls in their number of household chores, 
shopping and errands, social relations, leisure pursuits, and public-service activities (Yelin et 
al. 1995). Patients of working age often experience diminished work capacity and even total 
work disability (see section 5.9). Katz (1995) found in a prospective study that people with 
RA, when compared with controls, could perform fewer “value activities” at the 
commencement of the study. Over a 5-year period, these RA patients suffered an 
approximately 10% further reduction in these activities compared to controls’ activities.  
Various factors in a patient’s life interfere to magnify each other. The loss of functional 
capacity and chronic pain associated with RA have profound effects on psychological well-
being and on interpersonal relationships (van der Heide et al. 1994, Newman and Mulligan 
2000). RA patients report more symptoms of depression than does the general population 
(Frank et al. 1988). On the other hand, psychosocial factors may significantly impact 
individual performance, e.g., HAQ disability (Scharloo et al. 1999, Escalante and del Rincón 
1999).
The proportion of severely crippled RA patients in the community has decreased in the last 
decades. In the 1930s, of those with chronic arthritis selected from the Finnish population, 41% 
were “totally disabled” (Holsti and Rantasalo 1936), but in 1989, of RA patients in Kuusamo, 
Finland, only 10% were “severely incapacitated” (Hakala and Nieminen 1996). The reasons for 
this favorable development are diverse. Multidisciplinary care including early treatment with 
DMARDs may have improved the prognosis for RA (Hakala et al. 1994b). The most likely 
explanation, however, is orthopedic surgery and the advent of joint replacement operations on 
large joints.  
The consequences of a disease have been classified as a flow chart of impairment?disability
?handicap in the former International Classification of Impairments, Disabilities, and 
Handicaps (ICIDH) of the World Health Organization. This classification has been revised to 
become the International Classification of Functioning, Disability, and Health (ICF; WHO 
2001) which further extends the scope of disability and allows description of the remaining 
capabilities and of contextual factors (see section 5.7.10). 
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The results of a disease can also be represented by the term “quality of life.” This can be 
regarded as a subjective understanding of the disease-related overall situation, compared to the 
more objective picture of the ICF approach. Reduced quality of life comes close to the concept 
of handicap. No overall agreement exists on how to define quality of life, and many non-
equivalent instruments serve for measurement. (Scott and Garrood 2000). The concept of 
quality of life has become a cornerstone of health economics; cost-utility analysis of 
interventions is based on measures of quality of life in terms of quality-adjusted life years 
(Homik and Suarez-Almazor 2004).  
5.7 Assessment of RA
5.7.1 General
The ability of a physician to take a clear history and perform a competent clinical examination 
is a starting point both of proper diagnosis of RA and of evaluation of any patient with RA. 
Evaluation can be divided into assessment of process, i.e., what happens during the course of 
the disease, and assessment of outcome or “end result”, i.e., cumulative consequences of the 
disease process (van Gestel and Stucki 1999, Pincus and Sokka 2003, Stucki and Sigl 2004). 
 The process measurements reflect current disease activity, and they fluctuate during the course 
of RA, whereas the outcome measurements gradually worsen. Outcome variables include joint 
erosions, function and disability, social, psychological and economic consequences, and 
mortality. Function and disability, however, contain aspects of both process and outcome. In 
early RA, function is impeded mainly by the impact of joint inflammation and is thus 
predominantly a process variable. In established disease, however, joint damage is a 
progressively more important cause of limitations, and function is predominantly an outcome 
variable (Scott et al. 2000). For all assessment, it is important to use a valid and standardized 
measure which is feasible, reproducible, and sensitive to change (Guillemin 2003).  However, 
many measures used are influenced by psychosocial factors and comorbidities (McFarlane and 
Brooks 1997) 
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5.7.2 Measurement of disease activity and outcome 
No single measure available covers all aspects of RA activity. Various approaches undertaken 
have led to selection of a core set of measurements to be included in clinical trials (Felson et al. 
1993, Tugwell and Boers 1993). As a result of international cooperation, the consensus reached 
as to the minimal set of measures to be included in RA clinical trials is as follows: a set of six 
process variables—number of tender joints, number of swollen joints, pain score on a visual 
analogue scale (VAS), patient’s global assessment of severity of RA on VAS, assessor’s global 
assessment on VAS, acute-phase reactant (erythrocyte sedimentation rate or C-reactive 
protein)—and two outcome variables—functional capacity by the Stanford Health Assessment 
Questionnaire (HAQ) and radiographic assessment of the joints of the hands and feet 
(Buchbinder et al. 1995, van Riel 2000).
5.7.3 Tender and swollen joints 
Detection of joint inflammation is central to assessment of  disease activity (Woolf 2003). An 
inflamed joint is typically tender and swollen, two characteristics, each providing different 
information: Tenderness is more sensitive to change and correlates with pain, whereas swelling 
correlates with acute phase reactants and radiographic progression (van Riel 2000).
5.7.4 Pain score 
Patients with RA usually report pain as their worst problem (Sokka 2003a). In measuring pain 
levels, the Visual Analogue Scale is the instrument most frequently used. The VAS is easy to 
use and, because of its continuous scale, sensitive to change. Further, it can be interpreted as a 
ratio scale. The ACR recommends the use of a 10 cm horizontal VAS with “no pain” at one 
end and “worst possible pain” at the other.
5.7.5 Global assessments of RA severity 
Patient’s and physician’s global assessment of RA severity measured on a VAS have, in 
clinical trials of RA, appeared to be the measures most sensitive to change, showing good 
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discriminative power, and being predictors of future disability (Wolfe and Cathey 1991, 
Buchbinder et al. 1995). The global measures are a type of sum indicator reflecting a patient’s 
status wider than merely physiological characteristics. Pain, depression, HAQ disability, or 
number of tender joints were correlates of patient’s global assessment of RA severity in one 
followup study (Smedstad et al. 1997). In the multivariate approach, however, only pain and 
depression retained a statistically significant impact on patient’s global assessment. A 
discrepancy may exist in the perception of RA activity between patient and physician. A 
patient’s global assessment lower than the physician’s was associated in a Brazilian study with 
low education (Nicolau et al. 2004). 
5.7.6 Acute-phase reactants 
Erythrocyte sedimentation rate (ESR, Westergren method, mm in the first hour) and C-reactive 
protein (CRP, mg/L) are non-specific measures of inflammation, but correlate with other 
disease activity variables and are sensitive to change (van Riel et al. 2000). ESR reflects the 
disease activity of the past few weeks, while shorter-term changes in activity are shown by 
CRP, which is less susceptible than ESR to disturbing factors. Time-integrated values of CRP 
correlate with progression of radiological damage (Plant et al. 2000).  
5.7.7 Stanford Health Assessment Questionnaire (HAQ) 
The disability index of the HAQ is a self-assessment questionnaire to determine the ability of a 
patient to perform several daily activities over the previous weeks (Fries et al. 1980, Table 2, 
section 5.7.10). It contains 20 questions divided into 8 subdimensions. Each question has four 
options for answering scored from 0 to 3; these are activities performed: without ANY 
difficulty (score of 0), with SOME difficulty (score of 1), with MUCH difficulty (2), and 
UNABLE to do (3). If the patient needs aids or devices or help, the specific activity is given a 
score of 2. Maximum scores per subdimension are added up and then divided by the number of 
subdimensions provided (at least six). The Finnish version of HAQ has been used since the 
early 1990s (Hakala et al. 1994a). 
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The HAQ is short, easy to process, and reliable, and is validated against many other variables. 
Several studies show its value in assessing short-term response to treatment (Bruce and Fries 
2003). Interpretation of HAQ score depends on disease stage, since aspects of disease activity 
as well as aspects of disease outcome will influence physical disability. In early RA, HAQ 
disability is mainly determined by inflammation and pain, but the effect of structural damage 
grows progressively over time (Scott et al. 2000, Welsing et al. 2001). Involvement of different 
joint areas makes differing contributions to overall disability (Wiles et al. 2000).  In studies on 
groups of early RA patients, the HAQ improves after start of drug therapy, reflecting treatment 
response and perhaps adjustment to the situation; on average, a steady increase at a slow rate 
occurs thereafter. The HAQ score of an individual patient has, however, a very variable course 
which is mainly determined by changes in disease activity (Kirwan 2001). Several patterns of 
longitudinal course of the HAQ – non-linear, chaotic and non-time-determined – are defined 
by Wolfe (2000). Pain is the most powerful individual determinant of the HAQ (Sokka et al. 
2000), which is also associated with age, gender, and psychosocial factors (Smedstad et 
al.1995, Scharloo et al. 1999, Escalante and del Rincón 1999, Wolfe 2000). Some 
modifications of the original HAQ have been developed (Wolfe 2001). 
Pincus et al. (2003) have shown that the pooled index of the patient questionnaire Core Data 
Set measures—patient’s global assessments, pain score, and the HAQ—appears to be as 
informative as are the pooled indices of all Core Data Set measures and of the assessor-derived 
ones in distinguishing between active treatment and placebo. 
5.7.8 Radiological assessment 
X-ray progression in RA is used both to follow the course of the disease by an objective 
measure and to assess long-term effects of treatment (Ory 2003). In longitudinal analysis, 
fluctuations in RA activity were related to changes in radiological progression, supporting the 
concept that disease activity causes radiological damage (Welsing et al. 2004). Many methods 
of radiographic assessment have been devised; among them, the Sharp and the Larsen scoring 
systems and their modifications (Sharp et al. 1971, Larsen et al. 1977), the most widely used, 
focus on the small joints of the hand and foot. The Larsen method scores radiological 
appearances of joints in the hands, wrists, and feet compared to a set of reference films for each 
joint. The joints scored on each side are I IP, II-V PIP, and I-V MCP in the hands, I IP and II-V 
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MTP in the feet, and the wrist as one joint. The range of score for each joint is from 0 to 5: 
normal appearance (0), slight abnormality (1), definite early abnormality (2), medium 
destructive abnormality (3), severe destructive abnormality (4), and mutilating abnormality (5). 
In calculating the total Larsen score, all individual joint scores are summed after multiplying 
the wrist scores by 5. The maximum total score (Larsen index) is 200 per patient. 
In addition to radiography, new techniques are available for imaging in RA, such as magnetic 
resonance imaging and ultrasound. Their exact place in RA diagnosis and assessment  require 
still more research (van der Heijde 2003). 
5.7.9 Indices of RA activity 
Variables in the core data set have been combined in indices of disease activity to provide a 
single outcome measure (Pincus and Sokka 2003). The Disease Activity Score (DAS) and the 
DAS28 are used widely in Europe. The DAS is a statistically derived index combining tender 
joints, swollen joints, ESR, and patient’s global assessment of disease activity and is based on 
treatment decisions of rheumatologists in daily clinical practice (van der Heijde et al. 1993). 
The original DAS is calculated by a 44-joint count for tenderness and swelling, while the more 
concise DAS28 is based on examination of 28 joints (Prevoo et al. 1995).
5.7.10 Psychological factors in RA 
In addition to physical symptoms and signs, RA makes a marked impact on a patient’s 
emotional and social functioning. On the other hand, all the effects of the disease are 
influenced by the individual’s psychological characteristics which determine adaptation to the 
chronic disease and its consequences (Smedstad et al. 1995, Newman and Mulligan 2000). For 
instance, much of the variation in HAQ remains unexplained by disease activity and 
radiographic score alone (Escalante and del Rincon 1999, Wolfe 2000, Sokka et al. 2000) and 
is probably influenced by psychological variables, such as self-efficacy, self-esteem, anxiety, 
depression, learned helplessness, locus of control, coping, and social support. Coping strategies 
and different types of illness perception have been shown in RA to contribute to health 
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outcomes (Scharloo et al. 1999). High self-efficacy scores were associated with favorable 
changes in health status measures over a 2-year followup (Brekke et al. 2001). 
5.7.11 Assessment of overall RA impact: the ICF approach 
To examine the entire bio-psycho-social impact of RA, the International Classification of 
Functioning, Disability, and Health (ICF) can serve as a valuable tool (Cieza and Stucki 2004, 
Stucki and Cieza 2004, Scott et al. 2005). The ICF was developed by the World Health 
Organization (2001) to provide a systematic coding scheme and a universal language for 
describing situations with regard to human functioning and its restrictions. The ICF organizes 
information into two parts, each with two components: 1) Functioning and Disability: a) Body 
Functions and Structures, b) Activities and Participation; and 2) Contextual Factors: c) 
Environmental Factors, d) Personal Factors.  Thus, the ICF offers a comprehensive framework 
covering not only disease consequences but also other characteristics of patients themselves 
and of the environment, all of which play an important role in any possible misfit between 
individual capability and environmental requirements, a misfit leading to disability in general 
and to work disability especially (Shanahan and Smith 1999, Cieza and Stucki 2004) (Figure 
1).
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Figure 1. Interactions between components of the International Classification of Functioning, 
Disability, and Health (ICF). (Reprint with permission from the WHO). 
The ICF in itself is not a measure of functioning, but information gathered by history or by any 
available generic or RA-specific questionnaire can be linked to the system of the ICF (Cieza et 
al. 2002). Table 2 shows the items of the HAQ linked to categories and subcategories of the 
ICF.
Health condition
(disorder or disease)
ActivitiesBody functions
and structures
Personal
factors
Environmental
factors
Participation
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Table 2. Questions from the Stanford Health Assessment Questionnaire (HAQ) disability index linked to 
(sub)categories of the International Classification of Functioning, Disability, and Health (ICF).  
HAQ question ICF 
code 
ICF 
category 
Subcategory 
of ”mobility” 
Are you able to:    
- Dress yourself, including tying shoelaces and doing buttons? d540 SC - 
- Shampoo your hair? d510 SC - 
- Stand up from a straight chair? d410 MOB BP 
- Get in and out of bed? d410 MOB BP 
- Cut your meat? d550 SC - 
- Lift a full cup or glass to your mouth? d445 MOB HA 
- Open a new milk carton? d445 MOB HA 
- Walk outdoors on flat ground d450 MOB MOV 
- Climb up five steps? d455 MOB MOV 
- Wash and dry your body? d510 SC - 
- Take a tub bath? d510 SC - 
- Get on and off the toilet? d530 SC - 
- Reach and get down a 5-pound object  
   (such as a bag of  sugar) from just above your head? 
d430 MOB HA 
- Bend down to pick up clothing from the floor?  d410 MOB BP 
- Open car doors? d445 MOB HA 
- Open jars which have been previously opened? d445 MOB HA 
- Turn faucets on and off? d445 MOB HA 
- Run errands and shop? d620 DL 
-
- Get in and out of a car? d470 MOB MOV 
- Do chores such as vacuuming or yardwork? d640 DL 
-
MOB = Mobility category 
    BP = Subcategory “Changing and maintaining body position”  
    HA = Subcategory “Carrying, moving and handling objects”  
    MOV = Subcategories “Walking and moving” and “Moving using transportation”  
SC = Self-care category 
DL = Domestic life category 
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5.7.12 Quality of life measures in RA 
Health-related quality of life is a different approach to the impact of RA (Guillemin 2000), and 
its measurement relies mainly on self-administered questionnaires (Scott et Garrood 2000). In 
addition to their use as outcome measures, these instruments form the basis of cost-utility 
analysis in health economics (Homik and Suarez-Almazor 2004).  
5.7.13 Evaluation of improvement 
In intervention studies, improvement in RA is the main target and is the most important factor 
to evaluate. Two sets of treatment response criteria have been developed: the American 
College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) 
criteria. Both methods are valid in clinical trials, both being able to discriminate between 
treatments and correlating with other disease variables, both process and outcome (Pincus and 
Sokka 2003). The ACR criteria for improvement are based on changes in the ACR Core Data 
Set measures (Felson et al. 1995). The baseline requirement is that all these measures should 
have values higher than 0 at study entry. The ACR20 response requires at least a 20% 
improvement in tender (68 counted) and swollen (66 counted) joint count plus a similar 
improvement in at least three of the five remaining core measures (patient’s and physician’s 
global assessments of the severity of RA, patient’s assessment of pain, ESR, and HAQ). The 
ACR50 response and ACR70 response are defined respectively, as 50% and 70% 
improvement. The ACR response is dichotomous: improvement Yes/No. The EULAR 
response criteria, on the other hand, are based on attained level and change in DAS (van Gestel 
et al. 1996). They classify a patient as a good, moderate, or non-responder. 
In analysis of treatment response in followup studies with repeated measurements, it is 
preferable also to take intermediate assessments into account. This can be accomplished by 
plotting the variables over time and calculating the area under the curve (AUC) for each patient 
in each group (Pham et al. 1999). The mean group AUCs can be statistically compared. An 
AUC analysis can be performed with a modification of the ACR improvement criteria. The 
numerical ACR (ACR-N) is determined by the smallest degree of improvement in percentage 
terms from baseline in three criteria: number of tender joints, number of swollen joints, and the 
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median of the five remaining measures of disease activity (patient’s and physician’s global 
assessment of RA severity, patient’s assessment of pain, ESR, and HAQ) (Bathon et al. 2000).
The ultimate goal of anti-rheumatic therapy is that patients achieve a remission in the disease. 
Improvement of 20% or 50% may retard but not prevent joint damage and functional disability 
(Pincus et al. 2004). The ACR has proposed a definition for remission which is based on six 
disease activity variables (four of which are core set variables): duration of morning stiffness 
not exceeding 15 minutes, no fatigue, no joint pain (by history), no joint tenderness or pain on 
motion, no soft tissue swelling in joints or tendon sheaths, ESR (Westergren method) < 
30mm/h for females and < 20mm/h for males (Pinals et al. 1981). Of these criteria, five or 
more must be fulfilled for at least 2 consecutive months. The EULAR criteria for remission are 
DAS28 < 2.6 or DAS < 1.6, neither of which, however, presupposes the absence of inflamed 
joints (Prevoo et al. 1996). At a DAS cut-off level of 1.6, the percentage of misclassification 
for patients in remission or not is 10%. 
5.8 Economic burden of RA 
5.8.1 General
RA imposes a substantial economic burden on society (Pugner at al. 2000, Cooper 2000, 
Newhall-Perry et al. 2000,  Kvien 2004). The total annual costs of RA in Sweden, with a 
population of 9 million, were estimated in 1994 to be about €350 million (approximately 
US$430 million) (Jonsson and Husberg 2000). Costs can be divided into direct and indirect 
(March and Lapsley 2001, Lubeck 2003). 
5.8.2 Direct costs 
Direct costs are defined as those which are actually paid, e.g., doctor visits, laboratory and x-
ray examinations, hospital costs, medication, transportation to the health provider, and special 
aids. The proportions of various components of costs differ according to health care system and 
duration of disease. With the exception of patients with recent-onset RA, hospitalization is 
responsible for the largest component (Guillemin et al. 2004). This situation may, however, 
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change because some of the new drugs for RA are very expensive. Among the highly 
dissimilar studies published, RA-related direct costs have been highly skewed with average 
annual costs ranging from US$2,299 to $8,500 (Lubeck 2003).
5.8.3 Indirect costs 
 Indirect costs consist of the resources lost (Lubeck 2003). These can be of two kinds. 
Morbidity costs are mainly the productivity losses of employed patients including reduced 
earnings and lost tax revenues. Mortality costs are the present value of lost productivity due to 
premature death caused by disease. In RA, the indirect costs are of major importance, 
accounting for 50 to 85% of the overall costs of the disease. The main components are sick 
leave, part-time work, and early retirement. Average indirect costs have ranged from US$1,600 
to $27,700 per patient-year, depending on which patients were included and on RA duration 
(Meenan et al. 1981, Jonsson et al. 1992, Kobelt et al. 1999, Newhall-Perry et al. 2000, 
Merkesdal et al. 2001, Cooper et al. 2002, Söderlin et al. 2003, Ruof et al. 2003, Hallert et al. 
2004). In the early course of RA, indirect costs are already high (Merkesdal et al. 2001, Hallert 
et al. 2004).
5.8.4 Intangible costs 
We can also talk about intangible costs (Lubeck 2003). These represent deterioration in 
patients’ quality of life, as well as that of their families and friends. Leisure and social 
opportunities are lost, and patients may suffer from disability, pain, and reduced self-esteem 
and well-being. These costs are extremely difficult to quantify and are often omitted from 
studies. This aspect of RA outcome can perhaps be assessed better with quality of life 
instruments (Scott and Garrood 2000, Homik and Suarez-Almazor 2004). 
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5.9 Loss of work capacity in RA 
5.9.1 General
The ability of a person to perform gainful work is a multi-factorial phenomenon dependent on 
a balance between work requirements and personal characteristics—physiological capacity, 
psychological characteristics, professional and social skills (Shanahan and Smith 1999), both 
of which receive different weightings in differing contexts. RA in most cases leads to 
diminished functional capacity and consequently to diminished work capacity, and often even 
to total work disability (Yelin et al. 1980, Mäkisara and Mäkisara 1982, Pincus et al. 1984, 
Mitchell et al. 1988, Yelin 1992, Badley et al. 2001, Sokka 2003b, Backman 2004). However, 
patients with comparable levels of disease activity and impairment may differ greatly in work 
capacity, due to the many components of capability to work and the demands of the job. The 
entire bio-psycho-social field can be mapped by utilizing the International Classification of 
Functioning, Disability, and Health (ICF).
5.9.2 Definition of  ”work disability” 
Data on RA-related work disability have featured in a large number of studies. These, however, 
have been performed with disparate approaches and in discordant settings and contexts (Table 
3). First, the demographic and clinical profiles of the patients have differed. Second, some 
studies have been cross-sectional and others longitudinal. Third, no social security systems of 
various countries are equivalent. Further, criteria for work disability have not been uniform. 
Most studies have used pre-term RA-related disability pension or cessation of work due to RA 
as their indicators of work disability. Not all studies, however, have defined RA or ill health as 
the cause of the work termination (Fex 1998, Ruof et al. 2003). In addition, many studies have 
failed to use any external criterion (EC; official database such as a pension register) for work 
disability measurement, but have relied on patient-reported (PR) information (Table 3), which 
carries a risk for recall bias.  
Permanent work disability represents, however, only a portion of the impact of RA on working 
capacity. Sick leaves are common, especially in patients with recent-onset RA (Mau et al. 
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1997). Further, sometimes a patient’s work capability recovers even after a long period of work 
disability, and he or she can return to gainful work. Thus, counting the number of days a 
patient is work-disabled due to RA during a certain period of time is a more sensitive and 
appropriate indicator. Work disability days reported by the patient also including sick leaves 
have been used in a study from Germany and in another from Sweden to estimate loss of 
productivity in a cohort of patients with early RA over a 3-year and a 1-year followup, 
respectively (Merkesdal et al. 2001, Hallert et al. 2004). Although RA patients may report their 
productivity losses adequately, (Merkesdal et al. 2005) data registered by authorities or by an 
insurance system are preferable, to rule out recall bias. Only one study from Germany has 
utilized any health-care payer data; it estimated direct and indirect costs for patients with 
established or late RA (mean disease duration 8.4 years) (Ruof et al  2003).
Table 3. (Next page) Permanent work disability in cross-sectional (CS) and  longitudinal (LO) studies 
on rheumatoid arthritis. Definition of work disability either by patient-report (PR) or by external 
criterion (EC).
* / ** studies from the same cohort 
FIN = Finland, Scand = Scandinavia, S = Sweden, NL = the Netherlands, G = Germany, UK = the 
United Kingdom, LT = Lithuania, CAN = Canada. 
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First author Year
publish
ed
Country Type Years of 
followup,
if stated 
N Disease 
duration at 
start/review
(years) 
Work
disabled % 
Definition
Yelin 1980 USA CS - 180 10 60 PR 
Meenan 1981 USA CS - 180 9 48 PR 
Mäkisara 1982 FIN CS - 495 10 50 EC 
Pincus 1984 USA LO 9 75 11/20 85 PR 
Yelin  1987 USA LO 4 306 10; 15; 30 50; 60; 90 PR 
Kaarela* 1987 FIN LO 8 103 <0.5/8 43 EC 
Jäntti* 1999 FIN LO 20 103 <0.5/20 80 EC 
Reisine 1989 USA CS - 122 NA 43 PR 
Borg 1991 Scand LO 2 83 <2/2 37 EC 
Callahan  1992 USA CS - 175 11 72 EC 
Eberhardt**  1993 S LO 3 62 <2/3 37 EC 
Fex** 1998 S LO 7 86 <2/7 44 EC 
Douglas 1995 NL CS - 119 2 55 PR 
Reisine 1995 USA LO 5 392 9/14 44 PR 
Allaire  1996 USA CS - 469 7 22 PR 
Mau 1996 G LO 6 73 <1/6 49 EC 
Fifield 1996 USA CS - 501 <3 16 PR 
Wolfe 1998 USA LO 10 456 10 31.5 PR 
van
Jaarsveld 
1998 NL CS - 221 2.7 35 PR 
Sokka 1999 FIN LO 9.9 82 <2/2; 9.9 19; 44 EC 
Albers 1999 NL CS - 76 2.8 51 EC 
de Roos 1999 USA CS - 960 11.2 27 PR 
Barrett  2000 UK LO 9 160 <0.5/1; 2; 10 23; 33; 39 PR 
Chorus 2000 NL CS - 720 11.9 33 PR 
Merkesdal  2001 G LO 3 133 <1/2.5 26 EC 
Young 2002 UK LO 5 353 <0.5/5 29 PR 
Häkkinen 2003 FIN LO 2 52 2 31 EC 
Hallert 2004 S LO 1 141 <1/1 12 EC 
Dadoniene 2004 LT CS - 238 10 48 PR 
Lacaille 2004 CAN CS - 581 10 27 PR 
Verstappen 2005 NL CS - 296 4.3 20 PR 
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5.9.3 Occurrence of permanent work disability 
A total of 15 studies on RA-related work disability have been cross-sectional and another 16 
longitudinal. Differences in population, setting, study design, disease duration, labor markets, 
and social security systems are considerable. The proportion of work disabled patients varies 
greatly (Table 3 and Figure 2), and this variation is larger among cross-sectional studies. Rates 
are in general higher in European countries than in the USA and Canada (Figure 3). This may 
be attributable to differences in the social security systems; i.e., welfare facilities are less 
generous, especially in the USA, than in Europe (Verstappen et al. 2004). Further, the 
flexibility of the labor market may also influence the work disability rate. 
In prospective studies on early RA, the work capacity of RA patients is endangered from the 
very start of the disease (Borg 1991, Eberhardt 1993, Mau 1996, Sokka 1999, Barrett 2000, 
Merkesdal 2001, Young 2002, Hallert 2004). Many patients lose their ability to work even 
during the first year of treatment. Figure 2 illustrates how percentages of permanent work 
disability at first rise steeply and then subside somewhat in the later course of the disease. The 
percentages at 20-year and 30-year disease duration are from very old cohorts, and the high 
numbers may be attributable to less effective drug treatment before the methotrexate era 
(Pincus et al. 1984, Yelin et al. 1987, Jäntti et al. 1999).
5.9.4 Associations of permanent work disability 
Work disability being a bio-psycho-social phenomenon, cessation of working life results from 
interactions between various physiological variables, social conditions, and work-related 
factors. Several studies have shown that older age, lower educational level, and longer duration 
of disease as well as its severity (higher clinical disease activity, lower functional capacity, 
more extensive structural joint damage), and physically demanding jobs elevate risk for 
permanent work disability. A review of results of the multivariate regression analyses are in 
Table 4. Results are parallel in comparing studies on early RA with those with of longer 
disease duration
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Figure 2. Permanent work disability in the cross-sectional and longitudinal studies in Table 3. Dotted 
lines: confidence ellipse
Figure 3.  Permanent work disability in the European and North American studies in Table 3. Dotted 
lines: confidence ellipse
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Functional disability in activities of daily living (high HAQ score) appears to be the best 
disease-related predictor of permanent work disability (Table 4). On the other hand, evidence 
that structural joint damage (high x-ray score) predicts work disability is  inconsistent. Low 
formal education level has been associated with work disability in most studies including this 
variable. Fewer years of schooling often result in a physically demanding occupation. 
Occupational heavy labor, either self-reported or by job title, has, in most studies in which it 
has been analyzed, been associated with RA-related permanent work disability. 
Evidence is strong that older people with RA have an increased chance of becoming work 
disabled (Table 4). The elderly tend to have a less favorable course of RA (Kuiper et al. 2001), 
and aging itself of course has adverse effects on working ability (Wegman 1999, Chan et al. 
2000). Performance capacity decreases by age, and long life entails debilitating disorders and 
diseases. Older people are, on average, less well educated and with less chance of successful 
vocational rehabilitation, and employers may be reluctant to employ them. Further, it is likely 
that disability pensions are awarded to them more easily. 
Some studies have shown that social- and work-related factors cause a larger impact on 
permanent work disability than do factors involving RA itself (Yelin et al. 1980, Callahan et al. 
1992). For work-related factors other than physical demand, such as job satisfaction, 
managerial occupation, career opportunities, financial situation, and working hours, evidence is 
absent or inconsistent for association with work disability (Chorus et al. 2001). 
The role of psychological function in the work disablement process has infrequently been 
examined. Behavioral coping has shown some effect (Chorus et al. 2001).Three prospective 
studies have found only weak evidence that RA patients with emotional problems are at 
increased risk for work disability (Borg et al. 1991, Fex et al. 1998, Wolfe and Hawley 1998), 
and evidence is inconsistent that individuals who experience high pain levels are more likely to 
be work disabled (Table 4).
Two recent reviews conclude that, in RA, low functional capacity (high HAQ score), physical 
job demands, older age, and low education level predict permanent work disability (Verstappen 
et al. 2004, de Croon et al. 2004).
30
5.9.5 Difficulties in comparison of studies 
Caution is needed when reviewing previous research. It is difficult, and may be even 
misleading, to compare studies with differing settings and approaches (cross-sectional or 
longitudinal). Comparison is further impeded by disparities in study populations with regard to 
age, disease severity, and occupational profile, as well as by national differences in social 
security systems. In addition, treatment strategy has changed profoundly during the last two 
decades; the older cohorts of RA patients are hardly comparable with recent ones. The 
occurrence rates for permanent work disability in longitudinal studies in countries with 
differing insurance systems have, however, been quite parallel (Table 3, Figure 3). Indirect 
costs (i.e., lost productivity) have dominated RA-related expense everywhere. Relationships of 
permanent work disability have been rather uniform, although variables analyzed are not the 
same in all studies (Table 4). 
5.9.6 Computation of loss of productivity 
Several studies have shown that work absence, by reducing individual earnings and society’s 
productivity, becomes the most expensive outcome of RA (Meenan et al. 1987, Jonsson et al. 
1992, Kobelt et al. 1999, Newhall-Perry et al. 2000, Merkesdal et al. 2001, Cooper et al. 2002, 
Söderlin et al. 2003, Ruof et al. 2003, Hallert et al. 2004). Most estimations of loss of 
productivity have included only permanent inability to work with only two German studies and 
one Swedish study including sick leaves, as well (Merkesdal et al. 2001, Ruof et al 2003, 
Hallert et al. 2004).
Two methods are commonly used for placing a monetary value on lost productivity caused by 
absence from work. In the human capital approach (HCA), an individual’s productivity is 
valued at its market price (Johannesson 1996): This is the expected or potential gross wage or 
salary including all employer’s contributions, while for self-employed persons, it is the gross 
personal income including statutory insurance expenses. The HCA is the most widely used 
method, and this is largely because of its simplicity. Another method, the friction cost approach 
(FCA), “assumes that someone currently unemployed will replace the disabled worker after a 
friction period but only if the level of unemployment is above the frictional unemployment” 
(Koopmanschap and Rutten 1996). The friction period is the time needed to replace a sick 
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worker, and it is supposed to begin when a worker is first absent. The friction costs include the 
expenses of hiring, replacing, and training new employees, as well as the lost productivity prior 
to absent workers being replaced and the decreased productivity output associated with these 
new employees. To estimate the value of lost productivity by the FCA, the length of friction 
periods and the friction costs need to be determined at first. Depending on the assumptions 
employed, the FCA in most cases yields estimates that are lower than the HCA estimates 
(Lofland et al. 2001). The HCA takes a societal perspective, while the FCA includes employer 
costs of hiring and training new employees. The validity of the FCA approach has, however, 
been questioned (Liljas 1998). In any case, estimates of lost productivity depend on data 
sources and methods used (Verstappen et al. 2005b). 
Almost all studies of lost productivity have focused only on days lost from the workplace. 
Productivity output can also be lost at the workplace because of diminished work performance 
(Steward et al 2003a). In a recent study on common pain conditions in the US workforce, the 
majority, about three-fourths, of the lost productive time was explained by reduced 
performance while at work, a so-called “presenteeism,” and not by work absence, 
“absenteeism” (Steward et al. 2003b). In chronic diseases like RA, presenteeism is likely to be 
smaller (Wang et al. 2003), but reliable evaluation methods are needed (Lofland et al. 2004). 
One effort in this field is the WHO Health and Work Performance Questionnaire, a novel 
instrument for the estimation of absenteeism and presenteeism (Kessler et al. 2003). By using 
this instrument in analysis of associations between chronic conditions and work performance in 
a group of reservation agents, customer service representatives, executives, and railroad 
engineers, those patients with self-reported arthritis/rheumatism reported 8.5 days of excess 
absenteeism and 15.6 days of excess presenteeism per year (Wang et al. 2003), with results 
adjusted for age, sex, education, occupation, and other conditions.
In addition to gainful work, unpaid work (household, home maintenance, care-giving, 
studying) also has societal significance and economic value but is not included in the HCA 
(Backman et al. 2004).  
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5.10 Treatment of RA 
5.10.1 General
The etiology of RA being unknown, no causal treatment is available. The purpose of treatment 
of RA is to relieve symptoms and signs of the disease, as well as to prevent permanent tissue 
damage and its consequences. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely 
used, due to their rapid analgesic effects. The invention of cortisone and its dramatic impact on 
symptoms of RA led to great enthusiasm in the 1940s, until the hazardous long-term 
consequences of chronic use of glucocorticoids emerged. Almost all disease-modifying 
antirheumatic drugs (DMARDs) currently used have been found “by chance,” either based on 
empirical observations or even by theoretical considerations which later have proven incorrect. 
Testing of the hypothesis that RA is a type of chronic infection led during the last century to 
the invention of compounds empirically shown to be beneficial in patients with RA: Gold 
compounds were the first, and later came sulfasalazine and antimalarials. The concept that RA 
is an autoimmune disease led to testing of immunosuppressive agents. Consequently, 
azathioprine, methotrexate, and cyclosporine came into clinical use from the 1980s on. 
Recently, increasing knowledge of mechanisms in the pathogenesis of RA has enabled 
development of the so-called “biological agents” targeting several cytokines and other 
mediators of inflammation. 
5.10.2 Traditional DMARDS 
Ample evidence from randomized clinical trials and observational studies prove that DMARDs 
can alter the clinical course of RA (Paulus et al. 1990). Treatment responses evaluated by ACR 
criteria are, however, modest: ACR20 response is observable in 23 to 65%, ACR50 response in 
9 to 35%, and ACR70 in 1 to 9% of the patients (Felson et al. 1998), with the highest 
percentages usually in patients on methotrexate treatment. Remissions, usually transient, occur 
in about 20% of patients. The effect of the drug is in many cases later lost, and adverse events 
also may force discontinuation of DMARD. Methotrexate has proven the drug with the most 
long-term treatment periods (Pincus et al. 1992).
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In addition to their reducing disease activity, several studies indicate that early and aggressive 
therapy with conventional DMARDs improves long-term outcome, including limitation of 
radiographic damage and better maintenance of physical function (van der Heijde et al. 1996, 
Munro et al. 1998, Abu-Shakra et al. 1998, Tsakonas et al. 2000, Pincus et al. 2002). Early 
institution of a DMARD is important; even a delay of treatment by 4 months may be critical 
(Lard et al. 2001). Most patients, however, benefit insufficiently. To optimize DMARD 
therapy, the so-called “sawtooth” strategy was proposed in the 1990s (Fries 1990, Fries et al. 
1996). It included six principles: early DMARD use, continual serial DMARD use, regular 
quantitative monitoring of disability to detect insidious progression, setting a disability ceiling 
for each individual patient, sequential change in DMARD treatment when the ceiling is 
reached, and deployment of analgesics and NSAIDs as adjunct rather than first-line therapy. 
With the sawtooth strategy, the remission rate can be increased to about 32% of patients 
(Möttönen et al. 1996). Radiographic progression has been milder in cohorts enrolled in the 
1990s than in earlier cohorts (Sokka et al. 2004). This may reflect more effective drug 
treatment but can also result from an evolution in the biology of RA toward being milder 
(Walji and Bykerk 2004).  
5.10.3 Role of glucocorticoids
In recent years, data on the potential ability of low-dose corticosteroids to slow radiographic 
progression in RA have created new interest concerning the optimal use of glucocorticoids 
(Kirwan 1995, Townsend et Saag 2004). In addition to long-term low-dose strategy, two other 
approaches have been used: step-down with a high initial dose later tapered off (the COBRA 
trial; Boers et al. 1997), and bridge therapy aimed at controlling symptoms in the period of 
high disease activity while awaiting the effect of a newly started DMARD (van Riel et al. 
1999). No doubt exists that corticosteroids as a therapeutic adjunct improve suppression of 
disease activity (Lee et Kavanaugh 2003). 
5.10.4 Combination treatment 
Some recent studies show that treatment of early RA with combinations of DMARDs is well 
tolerated and provides a better clinical response than does treatment with a single DMARD. 
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Not all studies, however, have found any difference in favor of the combination treatment 
(Maillefert et al. 2003). In the Dutch Combinatietherapie Bij Rheumatoïde Arthritis (COBRA) 
study on treatment of early RA, an initial step-down combination of high-dose prednisolone, 
methotrexate, and sulfasalazine for 6 months was compared to monotherapy with sulfasalazine 
(Boers et al. 1997). Regardless of the subsequent antirheumatic therapy, the combination 
showed better suppression of the rate of radiological progression which was detectable even 
after 4- to 5-year followup (Landewe et al. 2002). Economic analysis showed that COBRA 
therapy added disease control in early RA at a lower or equal cost than did sulfasalazine 
(Korthals-de Bos et al. 2004). 
The FIN-RACo trial group has recently reported the 5-year clinical results of the FIN-RACo 
(Finnish Rheumatoid Arthritis Combination Therapy) trial—an open, randomized, followup 
trial—comparing the efficacy and safety of initial therapy with a combination of DMARDs vs. 
that of single DMARD in 195 patients with early RA. A total of 178 patients completed the 2-
year followup (Möttönen et al. 1999), and of these, 160 (78 in the combination group and 82 in 
the single group) completed the 5-year extension study (Korpela et al. 2004). At the 2-year 
visit, about 75% of the patients showed an ACR50 response, and remission was achieved by 
40% in the combination-DMARD group and 18% in the single-DMARD group. No significant 
difference emerged in rate of remissions at 5 years; the corresponding percentages were 28% 
and 22%. Progression of radiological joint damage, however, was less for patients in the 
combination group than for those in the single-drug group over the entire followup period: 
median Larsen radiological damage scores at baseline, 2 years, and 5 years were 0 vs. 2, 4 vs. 
12, and 11 vs. 24, respectively. 
Calgüneri et al. (1999) compared treatment with a single DMARD (hydroxychloroquine or 
sulfasalazine or methotrexate),  treatment with a combination of methotrexate and 
hydroxychloroquine or methotrexate and sulfasalazine, and treatment with a combination of all 
three drugs. The patients on combination therapies improved more than did those on a single 
DMARD, and the combination of three DMARDs was more effective than the 2-drug 
combinations. The rates of ACR remission at 2 years were 32%, 45% , and 60% in 1-, 2-, and 
3-DMARD groups, respectively.
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In the TICORA (tight control for rheumatoid arthritis) study, applying tight followup and 
continuous intensive treatment with DMARDs and glucocorticoids enabled as high as 65% of 
patients to fulfill the EULAR remission criteria, which are not as strict as the ACR criteria, 
however (Grigor et al. 2004). 
5.10.5 Biological agents 
Recently, biological agents, especially drugs inhibiting function of TNF-? (tumor-necrosis 
factor ?) have been shown to be effective in patients with severe acute or chronic RA. The anti-
TNF drugs: infliximab, etanercept, and adalimmumab rapidly neutralize the surplus of the 
target cytokine, and the treatment response appears during the first 2 weeks. In randomized 
clinical trials, responses to TNF-? inhibitors have been better than those to conventional 
DMARD monotherapy (Bathon et al. 2000). Infliximab is recommended to be used with 
methotrexate (Maini et al. 1998, Lipsky et al. 2000), and a combination of etanercept with 
methotrexate seems to have an additive effect (Klareskog et al. 2004). The anti-TNF therapies 
also effectively stop the progression of joint destruction. About 30% of patients, however, do 
not respond adequately, or the effect is slowly lost. Drawbacks of the biologic agents include a 
risk for severe infections, especially tuberculosis, and a potential risk for malignancies and for 
other, at present unsuspected, long-term adverse events (Lee et Kavanaugh 2003). Further, in 
contrast to the cheap old DMARDs, the new drugs are very expensive.
5.10.6 Impact of treatment on work capacity 
Few studies of RA have focused on the impact of patient management on work capacity. 
Lower risk for work disability was associated with early control of RA in a longitudinal study 
from the USA (Wolfe et Hawley 1998). A comparison of two historical cohorts from the 
Norfolk Arthritis Register failed to show improvement in work disability rates (Barrett et al. 
2000). In a Finnish cohort starting in the 1990s, patients’ functional capacity maintained 
favorably over a 5-year followup (Häkkinen et al. 2004), although 31% of the patients became 
permanently work disabled during the first 2 years (Häkkinen et al. 2003).
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Only two prospective clinical trials have included work capability as an outcome measure. 
Borg et al. (1991) studied the effect of early vs. delayed initiation of auranofin on the ability to 
maintain regular work in a placebo-controlled, double-blind 24-month study of 83 patients with 
early RA who were gainfully employed at onset. Of these patients, 42 received auranofin 6 mg 
daily and 41 received placebo. Patients in both groups could be withdrawn from the double-
blind drug therapy for insufficient therapeutic effect or for side effects and switched to open 
DMARD therapy. At the end of this study, 27 patients in the auranofin group were on the trial 
drug vs.14 in the placebo group. Of the 42 individuals starting auranofin, 23 were still 
gainfully employed vs. 12 starting with placebo. The respective numbers reporting RA-related 
cessation of work were 13 and 16. In multivariate analysis of predictors for work disability, 
treatment group had a slight effect (P <0.10).   
In 1999, Yelin et al. (2003) compared the patient-reported employment status of 238 RA 
patients who had been in clinical trials of etanercept and were currently taking the medication 
with the status of 259 RA patients in an observational study who had taken no etanercept. All 
patients had established or late RA with a mean disease duration of 16 years. At diagnosis, 
77% of future etanercept users were employed vs. 75% of those who did not take that 
medication. At the time of the study interview, 71% of the former group and 55% of the latter 
group were employed. This difference widened to 20 percentage points after adjustments for 
other variables. On average, the etanercept group worked a mean 7.4 more hours per week in 
1999 than did the no-etanercept group.
A non-validated “work productivity” score was included as an outcome in a 52-week double-
blind controlled trial comparing the efficacy of leflunomide or methotrexate with placebo 
(Strand et al. 1999). Of the patients, about 40% had early (<2 years) RA, and the same 
proportion had late (>5 years) disease. The patients were asked to rank their difficulty with 
work-related activities due to health problems and health concerns on a 6-point scale (1 = none, 
6 = can’t do it). The scores were presented on a 0 to 100 scale with higher scores reflecting 
higher productivity at home, school, and work. At the end point, significant improvement in 
work productivity score appeared during treatment with both leflunomide (P <0.001) and 
methotrexate (P <0.05) compared to placebo. This improvement correlated with ACR 
responder rates of ?20% and ?50%. Functioning and health-related quality of life improved as 
well.
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If effective treatment results in maintenance of patients’ work capacity, savings for society can 
be considerable. So far, only a substudy of the COBRA trial has estimated the economic 
impact of treatment. In the first 28 weeks, the indirect costs per patient with combined step-
down prednisolone, methotrexate, and sulfasalazine compared to sulfasalazine alone were 
US$2,578 and $3,638, respectively, and the total costs $5,931 and $7,853 (Korthals-de Bos et 
al. 2004). 
5.10.7 Rehabilitation
Rehabilitation, an adjunct of treatment of patients with RA, can be defined as minimizing the 
consequences of the disease (Straaton et al. 1992, Allaire et al. 1993 and 1996). Planning of 
rehabilitation can benefit from utilization of the International Classification of Functioning, 
Disability, and Health (ICF) (WHO 2001). In this scheme, disease consequences are divided 
into three areas: body functions and structures, activities, and participation. In addition to these, 
successful rehabilitation requires comprehensive mapping of the patient’s entire psycho-social 
field, i.e., the contextual, personal and environmental, factors in the ICF. The best possible 
level in each sector is the aim, and this is targeted by multidisciplinary use of rehabilitative 
treatment modalities: exercise, aids and devices, physical modalities, occupational therapy, 
patient education, psychological interventions, and vocational rehabilitation. Despite positive 
clinical experience, scientific evidence as to the effectiveness of rehabilitative interventions is 
scanty (Vliet Vlieland 2003). In a recent randomized controlled trial, however, vocational 
rehabilitation had a positive impact on maintenance of work (Allaire et al 2003). The 
importance of early intervention has been stressed  by Marnetoft (2002). 
5.11 Finnish social security system   
Finland has a statutory national health insurance system. If a resident of Finland, on account of 
illness, becomes temporarily unable to perform his or her regular job or another similar job, he 
or she is entitled to a sickness allowance as compensation for lost income. This is payable to 
persons between ages 16 and 64 and can be awarded to those both employed and self-
employed, as well as to those involuntarily unemployed. Self-employment may also take the 
form of household work or studies. Sickness allowance is paid after completion of a waiting 
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period comprising the first day of work incapacity and the following 9 weekdays (from 
Monday through Saturday). This waiting period is, however, waived if incapacity due to the 
same illness recurs before 30 days have elapsed since the end of the previous payment. 
Amount of sickness allowance is calculated on the basis of the most recent earnings assessed 
by tax authorities (for details, see Appendix 1). The allowance is paid for weekdays (including 
Saturday) for up to 300 days, i.e., for about one year. The claim for sickness allowance must be 
accompanied by a certificate issued by a doctor or a hospital documenting the claimant’s 
incapacity for work (KELA - the Social Insurance Institution of Finland 2000). 
The Social Insurance Institution of Finland is under law required to assess an individual’s need 
for rehabilitation, at the latest, when he or she has received sickness allowance for 60 days. 
Those whose work and earnings capacity is significantly impaired are entitled to the necessary 
vocational training or coaching to maintain or enhance their work capacity, and are eligible for 
a cash benefit called the rehabilitation allowance for the duration of their participation in a 
rehabilitation program, which means they will be absent from their regular jobs. 
If work incapacity persists for at least one year and prevents a person from engaging in gainful 
employment or from working in his or her own household, he or she can apply for a disability 
pension. When a claim for this pension is filed, the claimant’s work ability is examined on the 
basis of a doctor’s statement by medical examiners. The pension can be permanent or of 
defined duration. Finland has two complementary pension systems: national pensions linked to 
residence in Finland and employment pensions linked to past employment. Statutory 
employment pension insurance covers all employees and self-employed persons.  
The Social Insurance Institution is responsible for sickness allowances and national pensions 
and maintains a register of all benefits awarded. The Central Pension Security Institute 
maintains a register on employment contracts and employment pensions. Until the year 2004, 
each Finn above the age of 65 years was entitled to a retirement pension, which could be 
awarded as a reduced early old-age pension from the age of 60. After that year, the legislation 
has changed somewhat. 
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6 AIMS OF THE STUDY
The purpose of the present study was to explore the maintenance of the work capacity of 162 
patients with recent-onset, active RA in the Finnish Rheumatoid Arthritis Combination-
Therapy Trial (FIN-RACo) cohort; the patients were available for the active workforce at study 
entry. The following questions were framed: 
1) What is  the impact of an initial combination-DMARD treatment compared to a single-
DMARD strategy on the number of resultant  work disability days? 
2) What are the baseline predictors of cumulative work disability and productivity loss? 
3) What is the impact of treatment response on prognosis for work capacity? 
4) What is the monetary value of RA-related loss of productivity caused by days off work, and 
what are its explanatory factors? 
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7 PATIENTS AND METHODS
7.1 Selection of patients and study design 
From April 1993 to May 1995, 199 patients with recent-onset RA were recruited into the 
Finnish Rheumatoid Arthritis Combination-Therapy Trial (FIN-RACo) a multicenter, 
randomized, open parallel-group study designed to compare the efficacy and the tolerability of 
continuous therapy with a combination of 3 DMARDs and prednisolone with those of single 
DMARD therapy with or without prednisolone. A total of 18 rheumatology centers and 32 
physicians participated. Patient selection criteria were as follows: 1) fulfillment of  the 
American College of Rheumatology (ACR; formerly, the American Rheumatism Association) 
1987 revised criteria for RA (Arnett et al. 1988), 2) age 18 to 65 years, 3) duration of 
symptoms of <2 years, and 4) active disease with ?3 swollen joints and at least three of the 
following: (a) erythrocyte sedimentation rate (ESR) of ?28 mm/hour or C-reactive protein 
(CRP) level of >19 mg/liter, (b) morning stiffness of ?29 minutes, (c) >5 swollen joints, or (d) 
>10 tender joints.
The following patients were excluded: those who had used DMARDs in the past or had 
undergone glucocorticoid therapy within the previous 2 weeks; patients with elevated serum 
creatinine or liver enzymes, with leuko- or thrombocytopenia, with active gastric ulcer, with 
suspected inability to comply with the protocol, with hypersensitivity to any study medication, 
or with a history of cancer or heavy use of alcohol; pregnant women or women of childbearing 
age but not using reliable methods of contraception.  
The study was conducted according to the Declaration of Helsinki. The protocol was approved 
by the national health authorities and by the ethics committees in all 18 participating hospitals. 
All patients gave their informed written consent. The patients were randomized to receive 
either combination therapy or a single-DMARD therapy for 2 years. After that the choice of 
treatment became unrestricted. Randomization was done centrally with sequentially numbered 
envelopes in blocks of 20, stratified according to rheumatoid-factor status. 
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The primary objective of treatment in both groups was induction of remission. Patients 
assigned to the combination-therapy group started with sulfasalazine 500 mg twice daily, 
methotrexate 7.5 mg/week, hydroxychloroquine 300 mg/day, and prednisolone 5 mg/day. This 
initial combination, if tolerated, was continued for 3 months. If the clinical improvement at 3 
months was under 50% in at least 2 of the 3 criteria (swollen joints, tender joints, and ESR or 
CRP), the dose of methotrexate was increased to 10 mg weekly and that of prednisolone to 7.5 
mg daily. Thereafter, the protocol also included subsequent flexible dose adjustments of 
sulfasalazine, methotrexate, and prednisolone with remission as a target. The highest dose from 
9 months on was 2 g/day for sulfasalazine, 15 mg weekly for methotrexate, 300 mg daily for 
hydroxychloroquine, and 10 mg daily for prednisolone, as shown in Table 5. On the other 
hand, if clinical improvement was over 50% at 3 to 12 months, the initial doses were not 
increased. If the attained 50% response was lost, the doses of DMARDs or prednisolone were 
increased, or both. If one or several components of the combination had to be discontinued for 
any reason, a combination of 3 DMARDs was restarted by replacing sulfasalazine and 
hydroxychloroquine with auranofin (3 to 6 mg daily) and methotrexate with azathioprine (2 mg 
per kg daily). Other DMARDs could also serve as substitutes. At least 50% improvement had 
to be achieved at 12 months; otherwise the treatment was defined as a failure, and treatment 
thereafter became unrestricted.
Table 5. Dosage of DMARDs and prednisolone in the combination-treatment group during the first 36 
weeks
 Weeks 
 0-1 2-11 12 16 20 24 36 
Methotrexate,  mg/week  2.5 7.5 7.5–10 7.5–10 7.5–10 7.5–12.5 7.5–15 
Sulfasalazine, g/day 1 1 1 1–1.5 1–2 1–2 1–2 
Hydroxychloroquine, g/day 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
Prednisolone, mg/day 5 5 5 5–7.5 5–10 2.5–10 0–10 
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The single-treatment strategy also targeted remission. Patients were treated continuously with 
one DMARD according to the “sawtooth” principle (Fries 1990). Sulfasalazine (2 g daily) 
served as the initial drug for all patients, and the dose was increased to 3 g daily at 3 months if 
clinically indicated. If the clinical response was less than 25% at 6 months or in case of an 
adverse event, the protocol required that sulfasalazine be replaced with methotrexate (7.5 to 15 
mg weekly), which, if tolerated, was given until at least 12 months of followup. Azathioprine 
could be used as the third DMARD, and further, D-penicillamine, auranofin, injectable gold, or 
podophyllotoxin sequentially, if treatment response was inadequate or if adverse events 
occurred. Simultaneous use of prednisolone up to 10 mg daily based on a decision by the 
treating physician was allowed for patients with continuous active disease. Patients of both 
treatment arms were allowed to receive intra-articular injections of glucocorticoids as needed; 
number of injections and amounts of glucocorticoids were recorded.
After 2 years, choice of DMARD and prednisolone treatments became unrestricted. The aim of 
treatment was still to achieve or maintain remission. Patients in the single-DMARD arm with 
inadequate response could also be treated with a combination of DMARDs. In the 
combination-therapy arm, methotrexate could be increased up to 25 mg per week, orally or 
parenterally, or sulfasalazine up to 3 g daily if clinically indicated and tolerated. 
If a patient reached remission during the first year with combination of the initial minimal 
doses, the drug doses were tapered, and prednisolone, methotrexate, sulfasalazine, and 
hydroxychloroquine could even be discontinued at 9, 18, 24, and 30 months, respectively 
(Table 5). For patients who reached remission later and not at the initial doses, prednisolone 
was the first drug to be tapered off (2.5 mg daily each month) and discontinued. If remission 
continued, then one DMARD at a time could be discontinued each year by a gradual decrease 
in its dosage ( at first, methotrexate by 2.5 mg every 3 months, then sulfasalazine by 0.5 g 
every 3 months). Hydroxychloroquine was the last DMARD to be discontinued. If RA 
reactivated, then the last medication combination with which remission was maintained was 
reinstituted.
The patients were assessed clinically at baseline and at months 1, 3, 4, 5, 6, 9, 12, 18, 24, 30, 
36, 42, 48, 54, and 60. In addition to a clinical examination during study visits, safety was 
monitored by laboratory tests done every 2 weeks from study outset for 3 months, then once a 
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month until 12 months, and then every second to third month. Tests included complete blood 
count, serum alanine aminotransferase and alkaline phosphatase activities, creatinine
concentration, and urine analysis for blood and protein. Chest radiographs were carried out at 
baseline and once a year thereafter. If serum enzyme activities exceeded twice the upper limit 
of normal, the medication dose was lowered, and if the blood white cell count decreased below 
3.5x109 per liter or the platelet count below 100x109  per liter, the use of study medication, 
except prednisolone, was interrupted. All adverse events were documented.  
The study was open. Clinical assessments for each patient were made by the same attending 
rheumatologist in each study center throughout the study, with few exceptions. Disease-activity 
assessment included the American College of Rheumatology Core Data Set (Felson et al. 
1993): count of swollen joints (66 joints examined) and tender joints (68 joints examined); 
duration of morning stiffness; patient’s and physician’s global assessment of RA severity on a 
visual analogue scale (VAS) from 0 (no symptoms) to 100 (most severe disease); patient’s 
assessment of pain on VAS from 0 to 100; patient’s assessment of disability by the Stanford 
Health Assessment Questionnaire (Fries 1980, Hakala et al. 1994a); and ESR and CRP 
measurements. Radiographs of the hands and the feet were obtained at entry and at 6, 12, 24, 
36, 48, and 60 months and scored in sequence by one and the same radiologist (Leena 
Laasonen) by the method of Larsen (1977). The radiologist was unaware of any patients’ 
treatment and clinical features. 
Of the 199 patients eligible and randomized, 4 refused at the start. Of the eventual 195 starting 
therapy, 97 were assigned to combination therapy and 98 to single-DMARD treatment. After 2 
years, the drug treatment strategy became unrestricted, and 51 patients originally randomized 
to single treatment underwent therapy with a combination of DMARDs (at least two DMARDs 
simultaneously), and 70 of the 78 RA patients in the original combination group who 
completed the 5-year followup continued to receive DMARD combinations. All patients in the 
combination-treatment arm as well as 63 and 62 patients in the single-treatment arm received 
methotrexate and prednisolone, respectively. The median number of DMARDs taken during 
the 5-year followup was three both in the original combination group (range 3 to 6) and in the 
original single group (range 1 to 8). No significant difference in occurrence of adverse events 
existed between the two groups either during the two first years or during the period between 
year 2 and year 5.
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Response to treatment was evaluated by utilizing the ACR Core Data Set measures and the 
ACR criteria for improvement in RA (Felson et al. 1993 and 1995). The ACR20 response 
requires at least a 20% improvement in tender and swollen joint count plus a similar 
improvement in at least three of the five remaining core measures (patient’s and physician’s 
global assessment of the severity of RA, patient’s assessment of pain, erythrocyte 
sedimentation rate, and HAQ). The ACR50 response was defined similarly. The ACR 
preliminary criteria for remission (Pinals et al. 1981) were modified in such a way that fatigue 
(a vaguely defined criterion) and duration definition were excluded, and a patient might be on 
any or no drug treatment. However, a patient in remission had to fulfill all the other five 
criteria (Table 6).
Table  6. The American College of Rheumatology (ACR) preliminary criteria for remission (Pinals et 
al. 1981) and the modified criteria used in the present study (FIN-RACo). 
 ACR preliminary 
criteria
FIN-RACo
criteria
 number of criteria 5 or more 5 (all) 
 duration for at least 2 months 0 
 duration of morning stiffness <15 min + + 
 no fatigue  + 0 
 no joint pain (by history) + + 
 no joint tenderness or pain when moving + + 
 no soft tissue swelling in joints or tendon sheaths + + 
 ESR: female <30 mm/h, male <20 mm/h + + 
ESR = erythrocyte sedimentation rate 
The measure of overall response (ACR-N) was determined by the smallest degree of 
improvement in percentage terms from baseline in three criteria: number of tender joints, 
number of swollen joints, and median of the five remaining measures of disease activity 
(Bathon et al. 2000). 
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At the 5-year followup visit, the patients completed—with the assistance of a registered 
specialist nurse—a questionnaire. Demographic data and duration of formal education were 
recorded. Employment status since study entry was determined including changes in hours at 
work, job title, and nature of work. The patients were classified into two groups by job title and 
by nature of work reported by the patient (physically demanding or physically light work). 
Further, those with professional/managerial jobs were recorded separately. The patients were 
asked for permission to access data on their sick leaves and pensions as recorded in the social 
insurance registers. Patients lost to followup were contacted by letter. For those who could not 
be contacted or withheld permission, information about sick leave and retirement came based 
on their informed consent at baseline from case records, including duplicate copies of doctors´ 
diagnoses and statements as to their possible incapacity for work (Figure 4).
The study population comprised the 162 patients who at baseline were not retired, i.e., were 
gainfully employed or at least available to the workforce. Demographic and clinical 
characteristics of these patients at study entry are shown in Table 7.
Table 7. Characteristics of the 162 rheumatoid arthritis patients at baseline
Characteristic  Value 
Female, % 62 
Age, years, mean ± SD (range) 46 ± 9 (21–64) 
Disease duration, months, median (range) 6 (2–24) 
Job demands, physically demanding / light 83/79 
Rheumatoid factor present, n (%) 116 (72) 
ESR, mm/h, mean ± SD 38 ± 23 
Number of swollen joints, mean  ± SD 14 ± 6 
Number of tender joints, mean ± SD 19 ± 9 
Physical function (HAQ score), mean  ± SD 0.9 ± 0.6 
Erosion in hand or foot radiographs, n (%) 81 (53) 
SD = standard deviation, ESR = erythrocyte sedimentation rate 
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Figure 4. Study flow. 
randomized199 patients   eligible and r
4 refused at start
2 lost to clinical followup
195 started FIN-RACo trial
97 received combination therapy
98 received single-drug therapy
162 available to workforce
160 assessable at 6 months
146 gave at 5 years
9 lost to clinical followup
2 died
3 withheld permission
16 with data from case records
42 without loss of productivity120 with loss of productivity
162 with data on workforce participation until 5 years
 written permission to access data as
recorded in social insurance registers
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Work disability is defined here as period of time during which a patient was on sick leave 
receiving a sickness allowance from the Social Insurance Institution, or on a disability pension 
due to RA. RA was identified in the pension register by code number “714” in the ICD-9 and 
by “M05” or “M06” in the ICD-10. The sickness allowance register does not contain 
information on diagnosis codes, which means that the sickness allowances may also be 
initiated by diseases other than RA. Our patients, however, were followed up strictly according 
to the study protocol, with all adverse events as well as concomitant diseases documented. The 
medical records of the 12 patients with severe adverse events, of the 2 patients with sick leave 
due to a cause other than RA at baseline, and of the 2 patients retired prematurely due to a 
disease other than RA were reviewed in depth including duplicate copies of doctors’ 
certificates about incapacity to work, and only sick leaves due to RA were included in the 
analysis. 
For each patient, cumulative duration was calculated for sick leaves and RA-related disability 
pensions. If a person was receiving a part-time (50%) disability pension, the number of days on 
pension was divided by 2. The number of each patient’s work disability days was divided by 
observation period (years), during which the patient was potentially employable (without 
taking RA into account). Accordingly, if a patient left the labor market due to retirement on an 
old-age pension or on a disability pension due to causes other than RA, the date of retirement 
defined the end of his or her observation period. If a patient was lost to followup or died, the 
date at which the last data were received for him or her determined the end of the observation. 
The period of time during which the patients were known to be potentially employable ranged 
from 0.5 to 5 years.  
Our definition of work disability does not cover all “sick days.” Very short sick leaves were 
not registered by the Social Insurance Institution and consequently were not included in our 
study, because of the minimum period of 10 weekdays (including Saturdays) for sickness 
allowance. Thus, sick leaves due to most ordinary infections were not included. This minimum 
period is waived, however, if incapacity due to the same illness recurs before 30 days have 
elapsed since the end of the previous payment. Consequently, even short sick leaves caused by 
longer-lasting conditions such as RA were more likely to be included.  
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The social insurance data contained the sums of allowances and pensions paid as compensation 
for lost income. The amount of sickness allowance in the Finnish system is calculated on the 
basis of the preceding year’s earnings assessed by the tax authorities. Based on the allowance 
paid over the first sick leave period, the income before contracting RA can be calculated by 
applying the formula backwards. For the patients with case record data on days off work but 
without data on benefits paid, the income of each job was that recorded by Statistics Finland 
(www.stat.fi).
For estimation of lost productivity, the human capital approach (HCA) (Johannesson 1996) 
was applied: a person’s productivity was valued at the market price. An employee’s 
productivity was defined as equaling the total costs to an employer (salary plus supplementary 
social welfare expenses), and a self-employed person’s productivity as equaling his or her 
personal income plus the statutory health and pension insurance expenses. Productivity after 
the first year was computed based on annual income indices of each branch of the economy 
from Statistics Finland with addition of the supplementary expenses (a statutory percentage of 
income) in every year (Appendix 2); these sums were converted to prices in 2002 by the 
general index of wages and salaries. For each patient, mean productivity per day over the 5-
year followup was calculated and multiplied by cumulative number of days off work to yield 
loss of productivity. For a person receiving a disability pension for part-time (50%) work, 
number of days on pension was divided by 2. Euros were converted to US dollars at the 
January 2004 exchange rate (1 euro = $1.22).
7.2 Linking of items of HAQ to ICF categories 
The items of HAQ (section 5.7.7) at 6 months were linked to activity limitations of the ICF 
(section 5.7.11, Table 2). The linking principles of Cieza et al. (2002) were applied with a two-
level classification procedure. The HAQ yielded three ICF categories: “mobility,” “self-care,” 
and “domestic life.” The category “mobility” was divided into three subcategories: “changing 
and maintaining body position;” “carrying, moving and handling objects;” and “walking and 
moving plus moving using transportation” (Table 2). Each (sub)category comprised at least 
two items (questions) of the HAQ questionnaire yielding 0 to 3 points, and the highest number 
of points separately in each of them defined the function score of a patient. 
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7.3 Statistical analyses 
Results are expressed as means with standard deviation (SD) and 95% confidence intervals 
(95% CI), and as medians with interquartile range (IQR). Confidence intervals for the means of 
work disability benefits (Study III) and for the means of cost of lost productivity (Study IV) 
were obtained by bias-corrected and accelerated bootstrapping (5,000 replications) (Efron et 
Tibshirani 1980), because of the skewed distribution of the variables. Normality of variables 
was evaluated by Shapiro-Wilk statistics.  
Statistical comparison between treatment groups (Study I) was made by Mann-Whitney test 
and by Hodges-Lehmann estimation of the shift of medians. Median regression, also known as 
least absolute value models, served to estimate adjusted medians. In Study III, patients were 
divided into four groups according to clinical treatment response at 6 months with the ACR 
criteria as boundary lines: remission, ACR50 improvement with some symptoms, ACR20 
improvement but less than ACR50, and less than ACR20 improvement. Statistical comparisons 
between response groups were made by Kruskal-Wallis test with Monte Carlo P-value and by 
permutation one-way ANOVA with general scores. The global test for differences was 
followed by pair-wise multiple comparisons by the Dwass-Steel-Chritchlow-Flinger method 
(Hollander and Wolfe 1999). In Study IV, statistical comparisons between the groups (quartiles 
of AUC of ACR-N and four groups for increase in number of erosions) were made by chi-
square test as well as permutation test and ANOVA with general scores, both with Monte 
Carlo P-values.
Retirement analysis (Study I) was based on product-limit estimation; Mantell-Cox test served 
to identify any differences. A Cox proportional hazards regression model with robust estimate 
of variance was used to estimate adjusted risks for retirement.  
In Study II, a continuation-ratio logistic model for ordinal response data was applied (Fienberg 
1980); the forward stepwise method was used in multivariate analysis of predictors of work 
disability days. The patients were divided into four categories according to cumulative duration 
of work incapacity per patient-observation year: 1) 0 days (N = 41), 2) 1 to 19 days (38), 3) 20 
to 149 days (42), and 4) 150 to 365 days (41). Linearity of trend was analyzed by Cuzick’s 
1985 test. Patient’s and physician’s global assessments (scale 0 to 100) were dichotomized at 
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50 (median rounded to the nearest tenth). The self-reported function (HAQ score) was 
dichotomized at 1.0. The Cox proportional hazards model with robust estimate of variance 
served to analyze the predictors of permanent RA-related disability pensions. In Study IV, a 
multiple imputation (Markov-chain Monte Carlo) method was applied to fill in missing values 
of individual HAQ questions. A continuation-ratio model for ordinal outcomes served for 
analysis of relationships of loss of productivity to other variables. Associations are summarized 
as odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals (95% CI).  
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8 RESULTS
8.1 General
Of the 162 patients available for the workforce at baseline, 80 were randomized to receive 
combination therapy (COMBI) for 2 years, while 82 were randomized to single-DMARD 
therapy (SINGLE). At baseline, 82% of the patients in the SINGLE group and 89% of those in 
the COMBI group were gainfully employed; one patient in each group worked part-time. Equal 
numbers of patients in the two groups were on sick leave because of RA: 25 (30%) in the 
SINGLE and 25 (31%) in the COMBI group. In addition, two patients in the SINGLE group 
were on sick leave due to reasons other than RA. An imbalance existed in the number of 
unemployed job-seekers at entry: 10 patients in the SINGLE arm (12%) vs. 4 (5%) in the 
COMBI arm. This imbalance leveled off, however, during followup, and a total of 18 and 14 
patients, respectively, were for some period unemployed; median duration of unemployment 
was 13 months in the SINGLE and 14 in the COMBI arm. One person in each group was in 
vocational training at study entry. In addition, at baseline, four patients in each group were 
doing housework, none of whom, however, housewives in the traditional sense; all had 
completed professional training, and with the exception of three, all did paid work for at least 
some time during the course of the study.  
During the followup, 10 patients in each group changed employment, and equal proportions 
experienced a change in their working conditions (12 patients in the SINGLE and 11 in the 
COMBI). Five patients in the SINGLE group and two patients in the COMBI retired due to 
age. For two other patients in the COMBI, the reason for pre-term retirement was a non-
rheumatic disease (myeloma, coronary heart disease). Two patients in the SINGLE group died 
during the study, one from myelodysplastic syndrome, the other from alcohol intoxication. 
At 5 years, we had data on the labor-force participation of 158 patients. We failed to contact 
four patients randomized to the SINGLE group who had discontinued followup. Five (6%) 
were unemployed in each study group. Three patients in the SINGLE arm and one in the 
COMBI arm were doing housework, and the same number were employed part-time outside 
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the home. Of the 162 patients, 146 gave their written permission to obtain social register data. 
For the remaining 16 (11 in SINGLE, 5 in COMBI) data about sick leave and retirement was 
obtained, based on their informed consent given at baseline, only from case records. Treatment 
groups were comparable with regard to most demographic and clinical variables (Table 8). 
More women, however, were in the SINGLE group (p = 0.11).   
Table 8. Characteristics of patients available for the workforce in the combination-drug (COMBI) and 
single-drug (SINGLE) groups at study entry.  
Characteristic Treatment group 
 COMBI SINGLE 
 (n=80) (n=82) 
Demographic:   
   Female/Male 45/35 56/26 
   Married, % 73 77 
   Age, years, mean ± SD 45 ± 9 46 ± 10 
   Duration of education, years, mean ± SD 11 ± 4 11 ± 3 
   Job title, physically demanding / light 41/39 42/40 
   Professional/managerial job, n (%) 18 (23) 14 (17) 
   Disease duration, months, median (range) 6 (2–22) 7 (2–24) 
   Rheumatoid factor present, n (%) 59 (74) 57 (70) 
Measures of disease activity:   
   ESR, mm/h, mean ± SD 37 ± 24 38 ± 20 
   Number of swollen joints, mean ± SD 14 ± 6 14 ± 7 
   Number of tender joints, mean ± SD 18 ± 8 20 ± 10 
   HAQ score, mean ± SD 0.8 ± 0.6 0.9 ± 0.6 
Radiographic:   
   Number with radiographs available 77 79 
   Larsen score, median (IQR) 2 (0–4) 2 (0–7) 
   Erosion in hand or foot radiographs, n (%) 39 (51) 43 (54) 
SD = standard deviation, ESR = erythrocyte sedimentation rate, HAQ = the Stanford Health 
Assessment Questionnaire, IQR = interquartile range. 
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8.2 Work disability days (Study I) 
Work disability days accumulated at almost steady, but differing rates in each treatment arm 
for the entire followup period (Figure 5). No deviation occurred in the SINGLE arm after 2 
years, although drug treatment became unrestricted at that time. In 5 years, the median 
cumulative duration of work disability per patient-observation year was 32 (IQR 6–293) days 
in the SINGLE group and 12 (0–54) days in the COMBI group (P = 0.008); the sex- and age-
adjusted medians were 37 (95% CI 24–50) and 18 (95% CI 5–31) (P = 0.009). Mean duration 
of work disability per patient-observation year was 128 days for the SINGLE group and 78 
days for the COMBI. The superiority of the combination treatment was primarily related to 
difference in cumulative duration of sick leaves—i.e., work disability with a maximal length of 
300 weekdays—between the groups: the median number of days on sick allowance per patient-
observation year was 30 (IQR 6–68) in the SINGLE group and 12 (IQR 0–44) in the COMBI 
(P = 0.002). The respective means were 48 and 23 days.  
Figure 5. Accumulation of work disability days for patients who initially received a single DMARD or 
a combination of DMARDs. (Reprint from Arthritis & Rheumatism, Vol 50,  Puolakka K, et al.,  
Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic 
drugs on the development of work disability in early rheumatoid arthritis: A five-year randomized 
followup trial, pp. 55-62, 2004, with permission from John Wiley & Sons, Inc.) 
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8.3 Work disability benefits (I) 
The median of the work disability benefits, i.e., the sum of sick allowances and RA-related 
disability pensions paid by the social insurance system per patient-observation year, was 
US$1,094 (IQR 121–8,409) for the SINGLE group and $372 (IQR 0–1,973) for the COMBI  
(P = 0.008, sex and age-adjusted P = 0.009). Mean benefits were $4,404 and $2,534. The 
overall difference between the groups during the 5 years was a total of $569,740. 
8.4 Loss of productivity (IV) 
As Figure 6 illustrates, 120 of the 162 (101 female, 61 male) patients experienced days off 
work causing loss of productivity over the 5-year followup; females more often (83; 82%) than 
males (37; 61%); P = 0.002. 
Figure 6. Loss of productivity over the 5-year followup for the 162 patients with early RA. 
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Over the 5-year followup, estimated mean loss in productivity was $40,501 (95% CI 31,187–
52,587). It was $8,805 (95% CI 6,784–11,160) per patient-observation year, for women $7,902 
(95% CI  5,927–10,414) and for men $10,300 (95% CI 6,575–15,736). Mean age-and sex-
adjusted loss of productivity per year was $10,260 (95% CI 7,338–13,865) in the SINGLE 
group and $7,313 (95% CI 4,826–10,539) in the COMBI group; the difference was $-2,947 
(95% CI -7,279–1,331,  P = 0.17).
Loss of productivity was estimated on the basis of personal income before contracting RA. 
This was calculated by the register data for 101 patients. For the remaining 19, incomes came 
from Statistics Finland. To test the validity of the statistical income data, we compared the 
calculated incomes of the 101 patients to annual incomes in their jobs according to Statistics 
Finland; difference between the means was -$574 (95% confidence interval -3,073–1,113), i.e., 
showing no significant difference. The income data of the 19 patients can thus be regarded as 
valid. Personal income before contracting RA had no predictive value for loss of productivity. 
Figure 7 shows loss of productivity per patient-year in each year of followup. In the first year, 
the loss was highest and was mostly (89%) because of sick leave (~work disability up to one 
year). After that, permanent work disability dominated progressively: 79%, 89%, 92%, and 
94% in the second, third, fourth, and fifth year, respectively. Total annual loss began to 
increase slowly after the second year. 
58
Figure 7. Loss of productivity because of sick leave and permanent work disability in each year of 
followup
8.5 RA-related permanent work disability (I) 
 In most cases, continuous work disability for over one year translated into a permanent 
dropping out of working life, but two patients receiving SINGLE therapy and one receiving 
COMBI therapy could resume working after about 2 years of followup. After 3 years, this was 
possible for only two patients originally randomized to the SINGLE treatment. During the 5-
year followup, 24 (30%) patients in the SINGLE arm and 16 (20%) patients in the COMBI arm 
retired on a permanent disability pension due to RA; one of them in the SINGLE group was 
working part-time. No significant difference, however, was found in those pensions; the 
product-limit estimator of the rate of pensions was 30% (95% CI 20–40) for the SINGLE and 
20% (95% CI 11–29) for the COMBI arm (P = 0.16). A considerable proportion of our 
patients, 18 (22%) in the SINGLE and 11 (14%) in the COMBI group, were continuously and 
eventually permanently unable to work right from the first month of followup. 
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8.6 Gainfully employed patients (I) 
Most studies on RA-related work disability have included only patients gainfully employed. To 
facilitate comparison, we analyzed this subset of our patients separately, i.e., we excluded 
patients who at baseline were unemployed, were doing household work, or were in vocational 
training. At baseline, 67 patients receiving SINGLE therapy (82% of the non-retired) and 71 
receiving COMBI therapy (89%) were employed gainfully. In this population, the median 
cumulative duration of sex- and age-adjusted work disability per patient-observation year was 
29 days (95% CI 18–39) in the SINGLE and 15 (95% CI 5–24) in the COMBI group (P = 
0.03). When those who were gainfully employed at baseline (N = 138) were compared to the 
rest of the patients (N = 24), no significant difference appeared in work disability days per 
patient-observation year (median: 19 vs. 57 days; p = 0.25), in job type (50% vs. 58% had a 
physically demanding occupation; P = 0.45), or in length of formal education (mean: 11 vs. 12 
years; P = 0.23). 
8.7 Predictors of cumulative work disability (II)
In univariate analysis, the initial combination treatment was protective against extension of 
work disability. On the other hand, risk factors were older age, low education level (<10 years 
of schooling), and high score (?50) in patient’s and in physician’s global assessments of RA 
severity, tender-joint count, ESR, and self-reported disability (HAQ score ?1.0). Physically 
demanding job did not quite reach statistical significance as a risk factor. 
In the forward stepwise multivariate model, patient’s and physician’s global assessments, 
HAQ, low education level, and age remained significant risk factors; the initial combination 
therapy was still protective. A linear trend was observable between work disability categories 
and patient’s global (P = 0.001) or physician’s global assessment (P <0.001), especially in the 
single-treatment arm.  
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8.8 Predictors of permanent RA-related disability pension (II)  
In univariate analysis, older age, low education level, patient’s and physician’s global 
assessments ?50, and HAQ disability (score ?1.0) were significant predictors. However, in 
multivariate analysis, only patient’s global assessment, HAQ, and age remained significant. 
8.9  Impact of early treatment response on maintenance of work capacity (III) 
The 159 patients assessed at 6 months were divided into groups according to their ACR 
response. Of these, 29 (18%) were in the clinical remission (group I), 66 (42%) attained an 
ACR50 response but not remission (group II), 29 (18%) achieved an ACR20 response but not 
an ACR50 (group III), whereas the response for 35 (22%) patients was less than the ACR20 
(group IV). These groups also differed in some other characteristics: Patients in group III had 
the most active RA at baseline, while those in group IV had the longest sick leave during the 
initial 6 months. Those patients in remission at 6 months (group I) used considerable sick leave 
during the first 6 months, but after that, their number of work disability days was minimal 
(Figure 8). The 6-month improvement was a surrogate of the remaining disease activity at that 
moment: For all activity variables except ESR, a monotonous trend appeared across response 
groups. The Larsen score was lowest in the remission group.  
A distinct monotonous trend appeared between the four response groups and cumulative 
duration of work disability per patient-observation year from 6 through 60 months of followup; 
medians (IQR) of work disability days were 0 (0–3), 4 (0–131), 16 (0–170), and 352 (16–365) 
in groups I, II, III, and IV ( P <0.001). Pair-wise multiple comparisons showed a significant 
difference between all groups except the ACR50 (II) and the ACR20 (III) groups (P = 0.71). 
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Figure 8. Work disability days during the first 6 months and thereafter by 6 month treatment response. 
Median (?) with IQR. 
From 6 through 60 months of followup, the social insurance system paid a total of US$533,600 
in work disability benefits. The mean cumulative benefit per patient-observation year was 
$3,355 (95% CI 2,514–4,198). A patient with a poor 6-month treatment response (in group IV) 
cost  Finland’s social insurance system US$7,226 per year more (95% CI 5,124–9,272) than 
did a patient in remission (Figure 9). The difference across the four response groups was 
significant (P <0.001).
62
Figure 9. Annual work disability benefits during 6 to 60 months by 6-month response group. I = 
remission, II = ACR50 but not remission, III = ACR20 but not ACR50, IV = no ACR20. Means (?)
with 95% CI. 
None of the 29 patients in remission (I) at 6 months became permanently work disabled as a 
result of RA during the 5-year followup, whereas 19 (54%) did so in the group without an 
ACR20 response (IV). If a patient was not in remission at 6 months, risk for permanent work 
disability was no better in the ACR50 (II) than in the ACR20 group (III): 23% vs. 21% of the 
patients in the respective groups ended with a permanent RA-related disability pension. Figure 
10 illustrates the age-, sex-, job type-, and education level-adjusted rates of RA-related 
permanent work disability in the four response groups. At 12 months, 30 patients were in 
remission; each of these had achieved at least an ACR50 response at 6 months. Over the 5-year 
followup, none of the 44 patients in remission either at 6 months or at 12 months ended with 
RA-related permanent work disability.  
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Figure 10. Rate of permanent RA-related disability pensions by 6-month treatment response. Groups: I 
= remission, II = ACR50 with some symptoms, III = ACR20 but not ACR50, IV = no ACR20. Age-,  
sex-, job-, education level-adjusted. (Reprint from Arthritis & Rheumatism, Vol 52,  Puolakka K, et al., 
Early suppression of disease activity is essential for maintenance of working capacity in patients with 
recent-onset rheumatoid arthritis: Five-year experience from the FIN-RACo trial, pp. 36-41, 2005, with 
permission from John Wiley & Sons, Inc.). 
8.10 Association with loss of productivity (IV)
Loss of productivity (section 8.4) was prominently associated with patients´ clinical 
improvement over the 5-year followup. When the patients were divided into groups according 
to quartiles of area under the curve (AUC) of the ACR-N measure, the inverse correlation with 
improvement was distinct: Age- and sex-adjusted mean loss of productivity per patient-year 
was US$1,343 (95% CI 394–2,630) and $18,242 (95% CI 13,008–24,219) for the highest 
(best) and lowest (worst) quartiles of AUC in ARC-N improvement, respectively (P <0.001 for 
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difference across groups). Loss of productivity was also related to increase in number of 
radiological erosions of the hands and feet, although less strongly (P = 0.045 for difference 
across the groups of 0, 1 to 4, 5 to 9, and ?10 erosions).
At 6 months, the mean HAQ score was 0.30 (SD 0.39) for women and 0.24 (SD 0.36) for men. 
The HAQ at 6 months was linked to the ICF to explore what kind of activity limitations were 
the best predictors of loss of productivity. The HAQ yielded three ICF categories, of which 
“mobility” was further divided into three subcategories (Table 2). Even a minimal increase in 
HAQ score or slightly diminished performance in any of these five categories and 
subcategories of the ICF was associated with loss of productivity in univariate analysis (Figure 
11). For multivariate analysis, the patients were divided into four groups according to the 
annual monetary value of lost productivity: 0 (N = 41), $1 to1,200 (N=38), $1,201 to 10,000 
(N=42), and over $10,000 (N=41). HAQ score >0 led to elevated odds entering a higher cost-
group in ordered logit models (age- and sex -adjusted odds ratio [OR] 5.4, 95% CI 3.0–10.8;
P <0.001), but in a separate multivariate model, of the five ICF (sub)categories, only disability 
(score >0) in “changing and maintaining body position” led to increased odds (OR 4.4, 95% CI 
1.6–12.2; P = 0.005). Age was a risk factor, as well (OR 1.1, 95% CI 1.0–1.1;  P <0.001).
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Figure 11. Loss of productivity per patient-year over a 5-year followup by 6-month disability: total 
Stanford Health Assessment Questionnaire (HAQ) score and separate items of HAQ linked to 
categories of  the International Classification of Functioning, Disability, and Health (ICF). Means (?
patients with score 0, ? patients with score >0)  with 95% confidence intervals. Subcategories of 
mobility category: A = changing and maintaining body position; B = carrying, moving, and handling 
objects; C =  walking and moving plus moving using transportation.  
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9 DISCUSSION
9.1 Monetary value of loss of productivity 
In this study, we could estimate with greater accuracy than before the monetary value of lost 
productivity in early RA by utilizing official register data on RA-related work disability days 
and on individual incomes as assessed by the tax authorities. Productivity losses because of 
sick leaves and because of RA-related disability pensions were estimated separately over the 5-
year followup, whereas almost all previous studies have included only permanent work 
disability. The loss of productivity caused by days off work was considerable, on average 
US$8,805 per patient-year. 
The two longitudinal studies, which also included sick leaves, had patient-reported days off 
work as an outcome and based their estimation of loss of productivity on the gross income of 
all gainfully employed people in a country (Merkesdal et al. 2001, Hallert et al. 2004). The 
average annual loss in the German study (Merkesdal et al. 2001), US$11,750 (SD 1,120), was 
somewhat higher than in ours ($8,805; 95% CI 6,784–11,160). An explanation may be 
disparities in therapy: half our patients initially received treatment with a combination of 
DMARDs, and our rate of permanent work disability was lower (25% in 5 years vs. 26% in 3 
years), despite our cohort’s including more active RA cases and fewer white-collar workers. 
The first year’s loss of productivity in the Swedish study (Hallert et al. 2004), US$10,646 (SD 
16,503) (1 euro = US$1.22), is comparable to our mean of $10,150. The Swedish patients had 
less active RA at baseline, and only 70% of them received DMARDs one year after inclusion, 
compared to 100% of our patients. Further, incomes differ between countries.  
Patient-reported data on sickness absence carry a risk for recall bias, and the mean income of 
the population may not be valid information as to the patients’ actual wages and salaries. In 
another German study, which utilized health-care payer’s data on medical costs and on 
sickness absence, mean annual sick leave costs of the gainfully employed patients were 
US$3,459, and mean annual work disability costs of the retired patients were $10,197 (1 euro = 
US$1.22) (Ruof et al. 2003). That study, however, was cross-sectional, and the patients had 
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established or late RA with mean disease duration of 8.4 years. Further, RA-related and other 
work disability could not be distinguished and the productivity costs did not include 
contributions by employers to social insurance. 
Our study had accurate data about RA-related days off work over time allowing estimation of 
time-related changes in loss of productivity. The loss was already substantial during the early 
course of the disease, as also estimated earlier (Merkesdal et al. 2001, Hallert et al. 2004); lost 
productivity was actually highest during the first year of followup and then was almost entirely 
attributable to days off work because of sick leave. From the first year on, risk for permanent 
work disability was high, as well. This parallels to others’ results (Borg et al. 1991, Eberhardt 
et al. 1993, Mau et al. 1996), although a wider comparison to studies done with less exact 
methods, with different approaches and settings, with populations differing with regard to age, 
disease severity, and occupational profile, and in countries with differing social security 
systems may not be very fruitful.  
We sought to secure the validity of our material against the shortcoming in social insurance 
data that the registers included no causes of sick leaves, by reviewing the case reports of 
patients with a probability of longer-term sick leave due to causes other than RA. According to 
Finnish legislation, short sick leaves due, for instance, to ordinary infections were not included, 
but short sick leaves caused by longer-lasting conditions such as RA were more likely to be 
included. More than two-thirds of the work disability days were because of disability pensions, 
the causes of which were confirmed by the code of the main diagnosis. Further, the majority of 
sick leave days were linked to these RA-related pensions. We had no social insurance register 
data for 16 patients. Until the end of followup, however, they regularly visited a study center at 
least every 6 months, and we could obtain data on their sick leaves and pensions from case 
records including duplicate copies of doctors´ statements with diagnoses. In short, it is most 
likely that nearly all RA-related work disability days were included in our analyses, with 
hardly any sickness-absence days included caused by other conditions. In calculation of lost 
productivity, we had to use income data from Statistics Finland for 19 patients. Comparison of 
the job-specific income from these statistics with individual incomes calculated on the basis of 
register data showed that the income data from statistics are valid. 
69
In the Finnish social security system, in addition to those gainfully employed, those doing 
household work are also entitled to work disability benefits; the same is true for students and 
for those involuntarily unemployed. As all these groups could become work disabled and 
receive work disability benefits, we chose to include them in our study. Further, none of the 
eight patients doing housework at baseline was a housewife in the traditional sense; all of them 
had completed professional training, and five were at least for some period gainfully employed 
during the 5-year followup. On the whole, the dynamics of working life caused both an influx 
into and an outflow from the labor force as well as changes in working conditions. A total of 
20 (12%) patients of the 162 changed employment, and a further 23 (14%) experienced a 
change in their working conditions during the study. Part-time work has not been very 
common in the Finnish labor market, and only four individuals were employed part-time at 5 
years. Earlier, Yelin et al. (1987) have reported the work dynamics of a retrospective cohort of 
RA patients with mean disease duration of 11 years. From the year of diagnosis, 19% of their 
patients changed jobs and a further 20% experienced a change in their working conditions.
Of our patients, 32 (20%) were for some period unemployed over the 5-year followup, but only 
the days off gainful work were, by definition, included in calculation of loss of productivity. 
Work disability days and lost productivity of individual patients were in the analysis 
proportioned according to the period of time a patient was known to be available to the 
workforce. This patient observation period ended before 5 years for seven patients because of 
retirement due to age, for two because of pre-term retirement due to non-rheumatic disease, 
and finally for two because of death. A further nine patients were for other reasons lost to 
followup.
Controversy prevails as to how to value what is known as the opportunity costs for individuals. 
We chose the most widely used method, the human capital approach (HCA), which estimates 
loss of productivity as a function of an individual’s wage or salary (Johannesson 1996, 
Koopmanschap and Rutten 1996) and thus the HCA allocates a zero euro figure to the 
opportunity costs of individuals who are not paid for work outside of the home, such as people 
working in their own household and students.
Our estimation of RA-related loss in work productivity was limited to days missed from the 
workplace. A disease, however, can cause reduced productivity at work, as well. This 
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“presenteeism” (Stewart et al. 2003a) was not estimated here, which obviously means 
underestimation of the indirect costs of RA in this study.  In a recent study of lost productivity 
time due to common pain conditions in the US workforce, most of the pain-related lost 
productivity time occurred while employees were at work and was in the form of reduced 
performance (Stewart et al. 2003b). The estimated presenteeism was greater than the 
absenteeism (work absence) for self-reported arthritis/rheumatism, as well (Wang et al. 2003).  
9.2 Impact of early aggressive treatment with a combination of DMARDs on 
work capacity 
Our hypothesis was that aggressive initial treatment, i.e., the combination of three DMARDs 
and prednisolone which had induced more remissions at 2 years (Möttönen et al. 1999), could 
reduce work disability days more than did the traditional “saw-tooth” treatment strategy with a 
single DMARD at a time. This turned out to be true, and this was the first time a study clearly 
showed the impact of a drug treatment for RA on patients’ ability to work. The between-group 
difference was most distinct for number of days on sick leave; the rates for permanent RA-
related disability pensions actually did not differ significantly between treatment arms. Initial 
treatment with a combination of DMARDs was, in multivariate analysis, the only protective 
baseline factor against work disability days. The number of adverse events in the COMBI arm 
was no higher than in the SINGLE arm (Möttönen et al. 1999, Korpela et al. 2004). The ACR 
responses achieved by the FIN-RACo combination treatment at 2 years were among the best 
ever reported with DMARD therapy. Actually, the percentage of improvement with each very 
expensive biologic agent has not been better, although comparison of differing studies may be 
misleading. The FIN-RACo trial was planned to compare the two treatment strategies; the 
study design does not allow comparison of the impact of individual DMARDs on maintenance 
of working capacity.
Despite the significant difference in work disability days in favor of the combination-treatment 
strategy, no significant difference existed between the SINGLE and COMBI groups in the 
monetary value of lost productivity. The broader distribution of this variable compared to days 
off work is the likely explanation: Variation in days is multiplied by variation in income. 
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Accumulation of work disability days was almost linear in both treatment arms over the entire 
5-year followup, and the absolute difference between arms increased steadily over time. It is 
remarkable that no deviation from the linear progression in cumulative days of work disability 
occurred in the SINGLE arm after 2 years, when treatment strategy became non-restricted, and 
those patients randomized to single treatment who had not responded adequately to the saw-
tooth strategy were switched to a combination of DMARDs and prednisolone. Our results lend 
further support to the concept of “window of opportunity” in the early course of RA (O’Dell 
2002).
In 1977, Luukkainen et al. had already shown that with gold, earlier treatment gives better 
results than its later initiation. The FIN-RACo Trial Group has demonstrated that if start of 
therapy with DMARDs is delayed, the frequency of remissions at 2 years is lower with single-
DMARD therapy but remains the same with COMBI therapy, when both are compared to 
earlier treatment (Möttönen et al. 2002). Early institution of a combination of DMARDs is 
important, as well, based on the positive effect of initial therapy with a combination of 
DMARDs on retardation of radiological progression at 2 years which continued at least up to 5 
years, despite liberation of therapy in both treatment arms after 2 years (Korpela et al. 2004). 
The COBRA Group has similar findings: An initial 6-month cycle of intensive combination 
therapy including high-dose glucocorticoids has resulted in sustained suppression of 
radiographic joint damage independent of subsequent therapy (Landewe et al. 2002). 
To explore the work dynamics of patients with RA and to increase the number of patients in 
our cohort, we also included patients who at baseline were not gainfully employed. However, 
when only gainfully employed patients were analyzed, the difference in favor of the 
combination-treatment arm was maintained; the smaller P value is likely to be due to the 
smaller sample size.  
The FIN-RACo Trial was a randomized but open study. The protocol of the work disability 
project was not, however, presented to the Trial Group until 1998, when the first patients had 
been followed up for almost 5 years. Consequently, at least in the early years of followup, 
which according to our results were decisive for prognosis, it was very unlikely that the 
clinicians would have dealt differently with work disability assessment in the treatment arms. 
Further, all decisions concerning longer sickness allowances and disability pensions were made 
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by a neutral external examiner in the Social Insurance Institution or in the pension insurance 
companies.  
9.3 Risk factors for diminished work capacity 
Older age and fewer years of schooling appeared as risks factors for diminished work capacity, 
as in almost all studies (Table 4). The only significant disease-related predictors of work 
disability days were the HAQ and the global assessments of RA severity by patient and by 
physician at baseline. Thus, the questionnaire measures of the ACR Core Data Set were far 
better predictors than were measures of inflammation and joint damage. This parallels to the 
results of Pincus et al. (2003), who found  that an index of the three core data set patient 
questionnaire measures distinguishes the efficacy of active treatment from that of placebo as 
effectively as the American College of Rheumatology 20% response criteria do. Both the HAQ 
and patient’s global assessment are a type of sum variable which also reflect the patient’s 
psychological constitution (Smedstad et al. 1997, Wolfe 2000), supporting the bio-psycho-
social concept of working ability and work disability.
The HAQ has appeared in studies as a predictor of work disability almost invariably (Table 4). 
This is in accordance with the finding that the early HAQ predicts future functional capacity 
(Leigh et Fries 1992). In early RA, like that of our patients at entry, HAQ scores are correlated 
with disease activity, and the usually low radiographic scores have little influence (Scott et al. 
2000).  Pain has been the most important individual determinant of the HAQ at least in 
established or late RA (Sokka et al. 2000), but much of the variation remains unexplained and 
may be influenced by psychosocial factors (Wolfe 2000).  
Global assessments of RA severity have been included in work disability studies infrequently 
(Callahan et al. 1992, Wolfe et Hawley 1998, Sokka et al. 1999), although these variables are 
sensitive to change in clinical trials and are predictors of future disability (Wolfe and Cathey 
1991, Buchbinder et al. 1995). Patients’ global assessment correlates independently with pain 
and depression (Smedstad et al. 1997). Baseline psychological measures were not assessed in 
the present study, and, in fact, few studies have included them, none having found any of them 
to be independent predictors of work disability (de Croon et al. 2004).
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In most studies in which this has been analyzed, RA-related permanent work disability has 
been associated with occupational heavy labor (Table 4). Here, however, a physically 
demanding job was not a significant risk factor, at least in part because of the crude measure of 
physical work demand: the job title. Other studies, however, have not used any better indicator 
of actual work load. Such a measure is obviously needed both for future studies and for the 
everyday clinic, because workplace and job characteristics evidently have an influence on 
one’s ability to continue working. Occupational evaluation should start promptly after 
diagnosis of RA in order to discover any need for adaptations (Gignac et al. 2004, Allaire 
2004). Vocational rehabilitation had a positive impact on maintaining a career in a recent US 
randomized controlled trial (Allaire et al 2003). Another report from the USA indicated, 
however, that the state-federal vocational system was underutilized (Straaton et al. 1996). The 
situation may be the same in Finland. 
The predictors of work disability can be serve as “red flags” warning the clinician of an 
ominous prognosis for the patient’s work capacity and of a risk for high societal costs. This 
may aid in choice of treatment strategies and in guiding a patient at risk into vocational 
rehabilitation before any loss of employment. 
9.4 Impact of treatment response on maintenance of work capacity 
One of our most important findings is that early treatment response appeared to be a strong 
predictor of future work capacity. Earlier, one-year followup variables have appeared as more 
accurate predictors of  5-year disability than were baseline variables (Wiles et al. 2000). 
Further, ACR20 and ACR50 responder rates at one year of followup correlate with “work 
productivity” score in a study comparing leflunomide and methotrexate with placebo (Strand et 
al. 1999).  In the present study, the induction of remission by 6 or 12 months translated into 
maintenance of work capacity over the entire 5-year followup. The situation was almost the 
opposite for patients without at least an ACR20 response at 6 months: more than half of them 
ended with a permanent RA-related disability pension. The RA-related pre-term retirement 
occurred early in the course of disease, 65% of cases during the first year of followup. Similar 
results have been reported elsewhere (Borg et al. 1991, Eberhardt et al. 1993, Mau et al. 1996). 
It was a surprise that the patients without remission at 6 months had a similar prognosis in 
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terms of working ability irrespective of achieving the ACR20 or the ACR50 response, which, 
however, significantly separated the patients with regard to remaining disease activity. In this 
respect, no safe range existed for disease activity at 6 months. This emphasizes remission as 
the ultimate goal of treatment and is parallel to the finding that improvement of 20% or 50% 
may retard but not prevent joint damage and functional disability (Pincus et al. 2004).  
We found the trend expected between treatment response and duration of sick leave over the 
preceding 6 months. Prolonged sick leave may impose injurious psychosocial consequences 
that also partly account for the risk for future work disability. This also underscores the 
importance of early aggressive treatment and prompt initiation of vocational rehabilitation 
when needed. 
The ACR response criteria include HAQ score. The 6-month HAQ alone was associated with 
loss of productivity over 5 years, and even a minimal HAQ disability (score >0) raised the 
odds of entering a higher cost group. Previously, the HAQ score at one year of followup was 
the best predictor of HAQ disability at 5 years (Wiles et al. 2000). In the present study, of the 
items of HAQ at 6 months, only diminished performance  in the ICF subcategory “changing 
and maintaining body position” (Table 2) was independently associated with higher loss of 
productivity. Thus, with regard to work capacity, the explanatory powers of the items of HAQ 
diverge. On the other hand, the ICF offers a useful conceptual framework for addressing 
various aspects of capability to work as well as activities of daily living and should be 
increasingly applied in clinical rheumatology. 
The favorable impact of successful treatment was further indicated by the distinct relationship 
of RA improvement over time (AUC of ACR-N) to savings in lost productivity.  Progression 
of radiological damage of joints in hands and feet was associated with lost productivity, as 
well.
These results point out the importance of early and aggressive RA treatment. However, from 
the present point of view, the initial “aggressive” combination treatment in the FIN-RACo trial 
was not very vigorous, at least in the first months of followup. The highest methotrexate dose 
during the first 2 years was 15 mg per week, and this dose was not allowed until 9 months 
onwards. In addition, despite remission as a target of the treatment in both groups, the protocol 
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regarded the ACR50 response to be sufficient in some situations: If clinical improvement at 3 
to 12 months was over 50%, doses were not increased. This is probably why the peak in 
remissions (N = 54) was not achieved until 2 years (Möttönen et al. 1999, Korpela et al. 2004). 
Further, the initial single treatment with sulfasalazine was continued at least up to 12 months if 
improvement at 6 months was ?25%, and only if response was less did sulfasalazine have to be 
switched to methotrexate. Accordingly, the decisive 6-month response was entirely related to 
efficacy of sulfasalazine in the single arm. After 2 years, a switch from single-DMARD 
therapy to treatment with a combination of DMARDs was allowed, as well as an increase in 
methotrexate dose up to 25 mg per week. Instituting of a more intensive treatment was, 
however, too late in most cases: only two patients could resume work capacity after 3 years. If 
long-term remission was induced, the FIN-RACo protocol included reducing of drug doses, but 
this resulted in relapses in many cases. 
A trial that compares a combination of DMARDs with step-up therapy in only those patients 
who need step-up therapy remains yet to be done. However, because of the good results and 
favorable security profile of the FIN-RACo combination, we can recommend it as a standard 
initial medication in recent-onset active RA. The methotrexate dose can be increased early to 
25 mg per week orally or subcutaneously and sulfasalazine to 3 g daily. The results of the 
TICORA study (Grigor et al. 2004) suggest that the FIN-RACo combination with a more rapid 
increase in drug dosage could have induced more remissions. Another question is, should 
patients have induction therapy with glucocorticoids or with TNF inhibitors (O’Dell 2004 and 
2005)? In a recent small study, 20 patients with early (<12 months) RA treated with 
methotrexate (MTX) were randomized to receive either infliximab or placebo for 12 months 
(Quinn et al. 2005) and were followed up for another 12 months. At one year, 78% and 67% of 
the MTX-plus-infliximab-treated patients fulfilled the ACR 50 and ACR70 response criteria, 
respectively, versus 40% and 30% of the MTX-plus-placebo-treated patients. Response was 
sustained in 70% of the MTX-plus-infliximab-treated patients at one year after cessation of 
induction therapy. Between-group differences according to the HAQ and RA Quality of Life 
questionnaires were maintained ( P <0.05), although differences in DAS28, ACR response, or 
radiographic scores were not. Working ability was not assessed as an outcome. Obviously, 
larger studies are needed on biologic drugs as an adjunct to a single DMARD or to a 
combination of DMARDs, preferably studies including cost-effectiveness analysis as well. 
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9.5 Socio- and pharmaco-economic implications 
In the present study, the mean monetary value of one year’s work absence was US$36,000. 
This means that if a young person loses his or her working ability forever, the societal cost in a 
lifetime can rise to hundreds of thousands of dollars. Inducing an early remission thus will 
result in substantial savings. Not only days at the workplace are lost or saved, however. 
Disease-related reduced performance while at work can also result in considerable productivity 
losses (Steward et al. 2003a and 2003b), but such presenteeism was not assessable here. The 
economic scope is even more extensive, if we consider the value of unpaid work, not to 
mention quality of life. 
We did not calculate or compare our patients’ direct medical costs, because most were 
determined by the study protocol. In any case, cost of drug treatment with conventional 
DMARDs can be regarded as very reasonable. This is in contrast to the very expensive 
biological agents,  none of which were used for any of our patients during the 5-year followup 
period. Of the anti-TNF agents, infliximab in combination with methotrexate, and etanercept 
alone have been more efficacious than is methotrexate alone in treatment of patients with early 
RA (Bathon et al. 2000, St Clair et al. 2004, Quinn et al. 2005). Addition of methotrexate to 
etanercept improves its efficacy further (Klareskog et al. 2004).  No comparison of the 
biological drugs with combinations of DMARDs, however, exists. In a longitudinal study of 
patients with both early and established RA, longer-term treatment with etanercept resulted in 
increased hours of employment (Yelin et al. 2003), but more research in the form of well-
designed randomized controlled trials should include work capacity as an outcome (Lacaille 
2005).
An important question is: Can more remissions be induced in early RA by adding a biological 
agent to a combination of DMARDs and prednisolone? Further, can induction treatment of 
defined duration yield longer-term benefit? Treating all recent-onset RA with biologicals for 
years seems economically untenable for society, at least at present, but we have no means to 
select those patients who will not respond adequately to conventional DMARDs and thus will 
benefit most from biologicals. Another burning question is: What is the best policy to treat 
patients on combination-DMARD therapy not in remission at 6 months? Our results suggest 
that more vigorous therapy should be instituted, at least for patients of working age. Is a TNF 
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inhibitor the best option? In any case, even expensive therapy actually lowers cost to society, if 
a patient’s working ability can be maintained. Consequently, at least if working ability is in 
danger, institution of an anti-TNF agent might be prudent. 
9.6 Can the results be generalized?
Can our findings be generalized and offer a prescription for our colleagues who are treating 
patients with RA? Our results come from a study of patients with recent-onset, active RA 
which compares two treatment strategies for their RA, treating them with a single DMARD or 
with a combination. Strictly speaking, the difference observed in work disability days refers 
only to the patients treated according to the protocol of this multi-center trial. Our cohort is 
representative, within its selection criteria, for Finnish patients with early active RA, because, 
for social insurance reasons, practically all new RA patients in Finland are referred to 
rheumatologists in outpatient clinics of the public hospitals, and the participating centers 
covered almost every region of the country. Between-country differences in patient profiles in 
terms of occupational and psychosocial variables of course may exist. Further, the social 
security system may have some influence on sick leave and work disability; rates of permanent 
RA-related work disability have been in general higher in European countries than in the USA 
(Table 3), where welfare facilities are more limited than in Europe. In addition, the flexibility 
of the labor force market may affect the work disability rate, and the monetary value of lost 
productivity is dependent on income level. Within these restrictions, our results may be 
generalized to patients with early RA.  
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10 CONCLUSIONS
This project was a prospective cohort substudy of the Finnish Rheumatoid Arthritis 
Combination-Therapy (FIN-RACo) Trial, a randomized clinical trial conducted from 1993 to 
2000. A total of 162 patients with recent-onset rheumatoid arthritis (RA), aged 18 to 65 and 
available to the workforce, were followed up for 5 years. The aims of the study were achieved, 
and the questions framed were answered as follows. 
10.1 Answers to the questions 
10.1.1 Impact of initial drug treatment strategy on work disability 
Aggressive initial treatment with a combination of DMARDs for 2 years led to statistically 
significantly better working ability and fewer days off work over the entire 5-year followup 
than did therapy with a single DMARD. In the single-drug arm, no deviation in the 
accumulation of work disability days occurred after 2 years; this provides support to the 
concept of window of opportunity during the early course of RA.
Our results indicate that the impact of RA on work capacity should be measured, instead of 
mere recording of permanent work disability, by a count of the days that patients are unable to 
work.
10.1.2 Baseline predictors of cumulative work disability and productivity loss
The only RA-related baseline variables predicting productivity loss were the global 
assessments of RA severity by patient and physician and the Stanford Health Assessment 
Questionnaire (HAQ). These questionnaire measures are simple and easy to use routinely in 
clinical practice, and high scores should be regarded as alarm signals for poor outcome, more 
lost work days, and high costs to society.
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Implementation of the International Classification of Functioning, Disability, and Health (ICF) 
provides new insight into the assessment of functional capacity, as well as into the mapping of 
workplace characteristics and other environmental and personal factors which may impact on 
capability to work. This can aid in choice of patients at risk for vocational rehabilitation before 
their loss of employment.  
10.1.3 Impact of treatment response on prognosis for work capacity 
The prognosis for a patient’s working ability was distinctly impacted by early treatment 
response. Remission during the first year translated into maintenance of work capacity whereas 
even an ACR50 response at 6 months was often inadequate to prevent permanent work 
disability and high costs to society. Further, failure to achieve an ACR20 response carried a 
very high risk for permanent work disability. 
10.1.4 Monetary value of RA-related loss of productivity 
During the 5-year followup, of 162 patients, 120 (75%) used sick leave or experienced longer-
term work disability or both, which led to lost productivity; these were women more often 
(82%) than men (61%) (P = 0.002). During the first year, the loss of productive time was 
highest, resulting mainly from sick leave (89%); thereafter, permanent work disability 
dominated.  
The monetary value of the work absence-related lost productivity estimated by the human 
capital approach was substantial, on average US$8,805 per patient-observation year (95% 
confidence interval 6,784–11,160), although all patients received remission-targeted DMARD 
therapy, and half underwent aggressive initial treatment with a combination of DMADRs. 
Rheumatoid arthritis is truly an expensive disease. 
10.2 Clinical implications 
In conclusion, the impact of RA on work capacity should be estimated by calculating days off 
work. Evaluating RA-related reduced work performance while in the workplace with valid 
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instruments will further broaden the concept of lost productivity in future. To minimize the 
substantial risk of productivity loss, all patients with active, recent-onset RA should be treated 
aggressively from the very start, with the target being early remission. ACR20 or ACR50 
responses are not satisfactory to prevent work disability. If remission is not achieved by 6 
months, more vigorous therapy should be instituted. The role of the expensive biological drugs 
in early RA needs more research. However, even an expensive drug may result in cost-savings 
to society if it maintains a patient’s working ability, as the average loss from one year’s work 
disability in our study was US$36,000.  
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Appendix 1 
CALCULATION OF SICKNESS ALLOWANCE (sums in euros) 
Amount of sickness allowance is calculated according to the preceding year’s personal income, 
as stated in Finnish law. Income = annual income assessed by tax authorities at the last 
taxation, with income acquisition expenses, expenses for travel to and from work, and trade 
union dues deducted. All monetary values are in euros. 
1993
The minimum allowance,  payable to all residents of Finland, is 10.63 per day. 
If income is less than 6,379.37 
the allowance is 10.63 + 30% of (income/300weekdays). 
If income is  6,379.37 to 19,222.20 
the allowance is 17.00 + 66% of (income minus 6,379.37)/300. 
If income is  19,222.20 to 32,036.44 
the allowance is 45.25 + 40% of (income minus 19,222.20)/300. 
If income is more than  32,036.44 
the allowance is 62.34 + 25% of (income minus 32,036.44)/300. 
1994
The minimum allowance, payable to all residents of Finland, is 10.92 per day. 
If income is less than 6,379.37 
the allowance is 10.63 + 30% of (income/300). 
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If income is less than  6,042.99, then the allowance is increased by 2.8%. 
If income is   6,379.37 to 19,222.20 
the allowance is  17.29 + 66% of (income minus 6,379.37)/300. 
If income is  19,222.20 to 32,036.44 
the allowance is 45.54 + 40% of (income minus 19,222.20)/300. 
If income is more than  32,036.44 
the allowance is 62.63 + 25% of (income minus 32,036.44)/300. 
1995
The minimum allowance, payable to all residents of Finland, is 11.08 per day. 
If income is less than 6,470.19 
the allowance is 10.63 + 30% of (income/300). 
If income is  6,470.19 to 19,222.20 
the allowance is 17.39 + 66% of (income minus 6,470.19)/300. 
If income is  19,496.34 to 32,492.23 
the allowance is 46.04 + 40% of (income minus 19,496.34)/300. 
If income is more than  32,492.23 
the allowance is  63.36 + 25% of (income minus 32,492.23)/300. 
1996
If income is less than  880.57 
no allowance is paid, but based on a means test, allowance of 10.09 is possible. 
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If income is  880.57 to 22,894.69 
the allowance is 70% of (0.955 x income minus 840.94)/300. 
If income is  22,894.69 to 35,222.61 
the allowance is 49.05 + 40% of (0.955 x income minus 21,864.43)/300. 
If income is more than 35,222.61 
the allowance is 64.75 + 25% of (0.955 x income minus 33,637.59)/300. 
1997
If income is less than  894.65 
no allowance is paid, but based on a means test, allowance of 10.09 is possible. 
If income is  894.65 to 23,296.23 
the allowance is 70% of (0.955 x income minus 854.39)/300. 
If income is  23,296.23 to 35,842.52 
the allowance is 49.92 + 40% of (0.955 x income minus 22,247.90)/300. 
If income is more than 35,842.52 
the allowance is 65.90 +  25% of (0.955 x income minus 34,229.61)/300. 
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Appendix 2 
CALCULATION OF THE MONETARY VALUE OF EACH PATIENT’S 
PRODUCTIVITY 
I  Patients with data on sickness absence and sickness allowance 
Calculation of the annual income assessed by tax authorities before the patients contracted RA 
was performed by doing the calculation formula of allowances backwards. 
When, the first sickness allowance was  paid in 1993 
If allowance was 10.63 (minimum) to 17.00,  
 income was 1000 x (daily allowance minus 10.63). 
If allowance was 17.00 to 45.24,    
 income was 454.55 x daily allowance minus 1,350.00 
If allowance was 45.25 to 62.33,  
 income was 750 x daily allowance minus 14,715.00. 
If allowance was 62.34 or over, 
 income was 1200 x daily allowance minus 42,768.00. 
Incomes are adjusted for a child supplement to the sickness allowance (1.45 for 1 child, 2.90 
for ?2 ). 
When, the first sickness allowance was  paid in 1994 
If allowance was 10.92 (minimum) to 17.28, 
 income was 1000 x (daily allowance minus 10.92). 
If allowance was 17.29 to 45.53,   
 income was 454,55 x daily allowance minus 1,350.00. 
If allowance was 45.54 to 62.62, 
 income was 750 x daily allowance minus 14,715.00. 
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If allowance was 62.64 or more, 
 income was 1200 x daily allowance minus 42,768.00. 
When, the first sickness allowance was paid in 1995 
If allowance was 11.08 to 17.38, 
 income was 1000 x (daily allowance minus 11.08). 
If allowance was 17.39 to 46.03, 
 income was 454.55 x daily allowance minus 1,434.00. 
If allowance was 46.04 to 63.35,  
 income was 750 x daily allowance minus 15,033.00. 
If allowance was 63.36 or more, 
 income was 1200 x daily allowance minus 43,538.00. 
When, the first sickness allowance was  paid in 1996 
If allowance was less than 49.06, 
 income was 448.766 x daily allowance + 880.57. 
If allowance was 49.06 to 64.75 
 income was 785.34 x daily allowance + 22,894.69. 
When, the first sickness allowance was paid in 1997 
If allowance was less than 49.93, 
 income was 488.766 x daily allowance + 894.65. 
The last RA patients in the study received their first sickness allowances in 1996 (for 4 
patients) and in 1997 (for 1 patient). 
?
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According to income tax law (TVL §93–95), the deducted average income acquisition 
expenses in each year (from the National Board of Taxation) were added, except for self-
employed persons. FIM = Finnish marks; € = euros. 
Year Number of 
people
Income
acquisition
expenses, FIM 
Journey 
expenses,
FIM
Trade dues, 
FIM
Altogether,
FIM
Expenses per 
person, € 
       
1992 2,450,000 3,945,000 3,105,000 2,055,000 9,105,000 625.04 
1993 2,472,075 3,646,000 3,083,000 2,413,000 9,142,000 621.98 
1994 2,447,112 3,591,000 3,262,000 2,648,000 9,501,000 653.00 
1995 2,462,947 2,788,000 3,066,000 2,633,000 8,487,000 579.55 
1996 2,488,687 2,854,000 3,237,000 2,688,000 8,779,000 593.29 
1997 2,507,555 3,427,000 3,370,000 2,618,000 9,415,000 631.49 
1998 2,543,626 3,535,000 3,410,000 2,643,000 9,588,000 633.97 
1999 2,582,452 4,121,000 3,848,000 2,634,000 10,603,000 690,54 
2000 2,625,553 4,735,000 4,378,000 2,687,000 11,800,000 755.89 
Income after the first year was calculated by use of annual income indices of various branches 
of the economy (process industry, private service, building, transport, municipalities, state, 
self-employed farmers, other self-employed persons) from Statistics Finland (www.stat.fi). 
For wage and salary earners, average supplementary social welfare expenses (sickness 
insurance, pension insurance, unemployment insurance, accident insurance, group life 
insurance) were added to income in each year: 
1993  38.0% 
1994  37.0% 
1995  35.0% 
from 1996 onwards  32.2% 
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 For self-employed farmers, the corresponding social insurance percentages were: 
1993  11.68% 
1994  12.23% 
1995  11.50% 
1996  12.84% 
1997  13.02% 
1998  12.85% 
1999  12.95% 
2000  12.88% 
For other self-employed persons, the statutory social insurance percentages were: 
1993  22.00% 
1994  22.55% 
1995  22.25% 
1996  21.60% 
1997  21.90% 
1998  21.90% 
1999  21.80% 
2000  21.80% 
***
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II  Patients with data on sickness absence but without data on allowances paid 
Wage and salary earners
The average income from each job in 2002 came from Statistics Finland. Income in the 
preceding years was calculated by indices of wages and salaries (general index and separately 
the index of transport jobs and of building jobs). Average supplementary social welfare 
expenses were added to income. 
Self-employed persons 
Average income declared to the Farmer’s Pension Insurance Institution and the Entrepreneur’s 
Pension Insurance Institution in each year was obtained. Studies indicate that declarations of 
income made to pension insurance institutions are deliberately about 20% low. Consequently, 
20% was added to the income as was the statutory social insurance percentages. 
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Appendix 3 
CALCULATION OF THE MONETARY VALUE OF EACH PATIENT’S LOST 
PRODUCTIVITY 
The value of each patient’s annual productivity was adjusted to 2002 prices by the general 
index of wages and salaries. Annual productivity was divided by 365 to yield productivity per 
day. Productivity per calender day was used, because number of working days per year differs 
between individuals. Mean daily productivity from 1993 over 2000 was calculated. 
The value of lost productivity was calculated by multiplying each patient’s daily productivity 
by the number of days of sickness absence periods.
